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ABSTRACT 	  	  	   Excessive	  fructose	  consumption	  in	  Western	  diets	  correlates	  with	  increases	  in	  obesity,	  insulin	  resistance,	  kidney	  disease,	  and	  non-­‐alcoholic	  fatty	  liver	  disease	  (NAFLD),	  collectively	  part	  of	  metabolic	  syndrome	  (MBS).	  Liver	  and	  kidneys	  metabolize	  50-­‐70%	  of	  ingested	  fructose,	  but	  the	  fate	  of	  remaining	  fructose	  remains	  poorly	  understood.	  Moreover, the correlation of fructose ingestion with MBS highlights 
the need for better understanding of whole-body fructose metabolism,	  in	  both	  health	  and	  disease. To that end, valid rodent models for fructose metabolism must reflect the same 
metabolism in humans.	  A serious autosomal recessive defect in fructose metabolism, 
called hereditary fructose intolerance (HFI), is caused by mutations in the aldolase B 
gene (ALDOB, human; Aldo2, mouse).	  With low levels of fructose exposure, HFI patients 
develop NAFLD and liver fibrosis, sharing pathologies with MBS. Targeting Aldo2 for 
deletion in mice (Aldo2-/-) provides a major step in validating that fructose metabolism in 
mice mimics that in humans. Like HFI patients, Aldo2-/- mice exposed to chronic, low-
	  	   x	  
level dietary fructose show failure to thrive, liver dysfunction, and potential mortality.	  
The fructose-induced symptoms of HFI and MBS result from flux through the ketohexokinase (KHK)-mediated pathway, and the metabolite Fru 1-P. Bioinformatic	  analysis	  reveals	  gene	  expression	  for	  this	  pathway	  is	  highest	  in	  liver,	  as	  expected;	  surprisingly,	  brain	  is	  predicted	  to	  have	  expression	  levels	  similar	  to	  kidney.	  This	  predicted	  gene	  expression	  is	  validated	  via	  RNA	  in	  situ	  hybridization,	  quantification	  of	  enzyme	  activities,	  presence	  of	  transport	  proteins,	  and	  measuring	  fructose	  oxidation	  rates	  in	  adult	  mice	  brains.	  Within	  the	  brain,	  regions	  of	  the	  cerebellum,	  hippocampus,	  cortex,	  and	  olfactory	  bulb	  show	  the	  highest	  population	  of	  cells	  expressing	  Fru-­‐1-­‐P	  pathway	  genes.	  In	  these	  regions,	  enzyme	  activities	  for	  both	  KHK	  and	  aldolase,	  and	  rates	  of	  fructolytic	  flux,	  are	  many	  times	  that	  seen	  in	  liver	  slices.	  Additionally,	  brains	  of	  mice	  on	  a	  high	  fructose	  diet	  show	  a	  three-­‐fold	  increase	  in	  KHK	  activity.	  This	  suggests	  that	  not	  only	  are	  these	  regions	  of	  the	  brain	  capable	  of	  metabolizing	  fructose,	  but	  that	  they	  are	  also	  capable	  of	  responding	  to	  increases	  in	  dietary	  fructose.	  This	  work	  provides	  a	  foundation	  for	  research	  of	  long-­‐term	  consequences	  of	  excessive	  fructose	  consumption	  in	  multiple	  organs.	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CHAPTER ONE: Introduction 
1.1 Popular Diets and Public Health: the effects of high sugar diets and the rise of 
obesity and metabolic syndrome 
Over the last 30 years, the increased intake of fructose has exceeded that of any other 
food group (Gaby, 2005). The World Health Organization recently released guidelines 
that fructose should make up not more than 5% of total daily caloric intake; however, in 
the United States (US), fructose may constitute up to 15% of daily caloric intake (Ouyang 
et al., 2008; Ishimoto et al., 2012; Moore et al., 2014). The rise in fructose consumption 
is correlated with an increase in obesity, where over half of all US adults are now 
considered overweight (Kuczmarski et al., 1994; Wickelgren, 1998). While fructose 
naturally occurs in fruits and honey, the majority of fructose is now entering the US diet 
in the form of high fructose corn syrup (HFCS) due to its use in processed foods. 
Worldwide, fructose intake has also increased in European countries, as well as emerging 
and developing countries, but at about half the rate as in the US (Tappy & Le, ).  
Mounting evidence from mouse models makes it clear that high amounts of 
fructose consumption not only leads to obesity, but also to the build up of fat droplets in 
the liver, hyperuricemia, and insulin resistance (Mayes, 1993). High-fructose diets in man 
and rodents also lead to an increase in visceral fat, although there is some debate over 
whether obesity is a risk factor for metabolic syndrome or an early onset symptom 
(Khitan & Kim, 2013). It is clear that in humans, both obesity and metabolic syndrome 
(MBS) correlate with the rise in fructose consumption (Goran et al., 2013). Other 
symptoms of metabolic syndrome in patients include the development of atherosclerosis, 
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lactic acidosis, dyslipidemia, and cataracts (Mayes, 1993; Douard & Ferraris, 2008). On a 
cellular level, acute concentrations of blood fructose levels can cause inflammation and 
cellular injury to liver and kidney cells (Bergheim et al., 2008; Nakayama et al., 2010), 
and sustained elevated fructose loads can lead to non-alcoholic fatty acid liver disease 
(NAFLD) (Ouyang et al., 2008; Vos & Lavine, 2013) and/or chronic kidney disease 
(Gersch et al., 2007; Ouyang et al., 2008; Thuy et al., 2008). 
 Alarmingly, increasing evidence has linked high fructose consumption, insulin 
resistance, and metabolic syndrome with deficits in learning, memory, and the 
development of dementia. Impaired insulin sensitivity adversely affects white matter 
structure and function (de la Monte & Tong, 2014). Insulin resistance in the brain affects 
both the hypothalamus, involved in regulating satiety and feeding behavior, as well as the 
hippocampus, involved in memory formation (Farooqui et al., 2012). High fructose diets 
impair learning in rats (Messier et al., 2007), and volume losses in the hippocampus and 
frontal lobe are seen in human patients with metabolic syndrome (Simopoulos, 2013). 
The mechanisms underlying the effects of high fructose loading on the brain are not 
completely understood and merit more investigation. 
 Obesity can be induced by overconsumption of glucose and fructose in both 
animal models and in man (Sievenpiper et al., 2012). Many studies have found that diets 
in rodents and humans that are isocaloric for glucose or fructose do not show a significant 
difference in body weight when the diets are not also high caloric (Sievenpiper et al., 
2012). However, subjects on high caloric high-fructose diets do show an increase in 
visceral fat and fat accumulation in the liver compared to high caloric high-glucose diets 
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(Moore et al., 2014). These differences may be due to the way that the two sugars are 
metabolized.  
There are two pathways for metabolizing fructose once it enters a cell: the KHK-
mediated Fru-1-P pathway, which is fructose specific, and the hexokinase (HK)-mediated 
Fru-6-P pathway, where fructose competes with glucose for phosphorylation by HK 
(Mayes, 1993). These two pathways differ mainly at the rate of phosphorylation of 
fructose, and the regulation of the flux through the pathway. Glycolysis is a tightly 
regulated pathway, especially at the level of HK and phosphofructokinase (Scrutton & 
Utter, 1968). The fructose-specific pathway utilizes a separate set of enzymes that don’t 
include HK and phosphofructokinase, and its flux is not allosterically regulated inside the 
cell (Table 1.1). Because of this, fructose metabolism via KHK-mediated 
phosphorylation can contribute to a pool of free triose-phosphates that is not feedback-
inhibited. Until recently, KHK activity was thought to only be present in the liver, and to 
a lesser extent, kidneys and small intestine, and that a physiologically functional KHK 
was not expressed in other organs (Asipu et al., 2003). Because of this, it was thought 
that the liver was the main site of the KHK-mediated Fru-1-P pathway, and that other 
organs such as adipose tissue metabolized fructose via HK and the Fru-6-P pathway 
(Froesch & Ginsberg, 1962). However, studies on purified, alternatively-spliced KHK 
isoforms have shown that both isoforms are active (Asipu et al., 2003), and studies in 
knockout (KO) mice have shown that they are both physiologically relevant (Ishimoto et 
al., 2012) (see Sections 1.2.2).  
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Table 1.1 Parameters and allosteric regulation of enzymes in fructose metabolism 
 
Hexokinase mediated pathway 
 
Ketohexokinase mediated pathway 
 
Enzyme Sugar Km (mM) 
allosteric 
regulation Enzyme Sugar Km (mM) 
allosteric 
regulation 
HK-I Fru 1.6-3.5a, b G6P KHK-C  Fru 0.2-0.5 c,d NA 
PFK Fru 6-P 0.047e AMP,  Fru 2,6-P2 
Aldolase 
B Fru 1-P 0.3
f NA 
Aldolase A Fru 1,6-P2 0.004
g  NA     
 
Abbreviations: HK – hexokinase; KHK – ketohexokinase; PFK – phosphofructokinase; Fru – 
fructose;  
NA – not applicable 
aSols & Crane, 1954  
bSchimke & Grossbard, 1968  
cAdelman et al., 1967  
dAsipu et al., 2003  
eDurante et al., 1995  
gPenhoet & Rutter, 1971  
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Ketohexokinase is specific for fructose phosphorylation, and is the hallmark 
enzyme of the Fru-1-P pathway for fructose metabolism (Bonthron et al., 1994). Other 
proteins and enzymes in the fructose metabolism pathway include the GLUTs capable of 
fructose transport, aldolase, and triose kinase. GLUT5 only transports fructose, with no 
quantifiable glucose-transporting activity (Rand et al., 1993), and together with KHK, is 
specific for fructose metabolism (Patel et al., 2015).  
Therefore, tissues expressing both GLUT5 and KHK have a metabolic pathway 
specific for fructose metabolism. Other tissues expressing GLUTs capable of transporting 
fructose can also contribute to over-all physiological fructose metabolism. Different 
combinations of expression of various fructose-transporting GLUTs, levels of KHK or 
HK expression, KHK isoform expression, and aldolase isozyme expression in tissues 
make the fates of fructose metabolites and the flux through the fructose metabolism 
pathway tissue-specific. The different enzymes in that participate in fructose metabolism 
are shown in Fig 1.1, and discussed in detail below. 
 
1.2 Enzymes Specific to Fructolysis  
The following section discusses the individual proteins in each class of proteins (GLUT 
transporters, enzymes that phosphorylate fructose, enzymes that cleave Fru 1-P or Fru 
1,6-P2, enzymes that catabolize the triose phosphates) in the fructolysis pathway in detail.  
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Fig. 1.1 Enzymes participating in fructose metabolism 
Fructose enters cells through a fructose-transporting GLUT. It is then metabolized either via the 
fructose-specific, ketohexokinase-mediated Fru-1-P pathway, or via the hexokinase-mediated 
Fru-6-P pathway where it is processed similar to glucose. The plasma membrane is represented 
by a double line, and the transport protein by the grey oval. Arrows represent either transport 
through a GLUT protein, or a step in catabolism. Enzymes are listed in bold, and metabolic 
intermediates in regular font.  
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1.2.1 GLUTs capable of fructose transport 
Hexoses, and some other small molecules such as uric acid and myo-inositol, are 
transported into the cells via the solute-like carrier 2A (SLC2A) family of proteins, the 
GLUTs. The transporters in the GLUT family are all facilitative transporters, with the 
exception of HMIT (GLUT13), which is a H+/myo-inositol symporter (Uldry, 2001). 
GLUT transporter proteins are all roughly 500 amino acids long and contain 12 
transmembrane helices. The family is organized into three classes based on sequence 
similarity, with substrate specificity determined by different conserved residues in each 
class (Manolescu et al., 2007; Mueckler & Thorens, 2013). Tissue distribution, preferred 
substrates identified so far, and responsiveness to insulin of 13 members of the  
GLUT family are summarized Table 1.2. GLUTs capable of transporting fructose are 
highlighted in bold. 
Conserved residues determining fructose-transporting ability. In order for a 
tissue to metabolize dietary fructose, it must first be able to transport fructose from the 
blood stream into its cells. Recently, the number of GLUTs determined to have fructose-
transporting capabilities has expanded. Previously, it was thought that only GLUT2 and 
GLUT5 were capable of transporting fructose; however, GLUT7 and GLUT9 also have 
fructose transporting ability (Doege et al., 2001; Manolescu et al., 2005; Anzai et al., 
2008). Determinants required for substrate specificity have been investigated in GLUTs 
known to transport fructose and used to predict other GLUTs that might also be capable 
of fructose transport. For example, replacing an isoleucine on transmembrane-domain 7  
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Table 1.2 Tissue distribution and substrate specificity of GLUT transportersa 
Class Protein Tissue Found Substratesb Local. c in Cell Stimulus to PM 
I GLUT1 
blood and blood-tissue 
barriers, brain, many 
fetal tissues 
Glc, Gal, Man, 
GlcN PM  
I GLUT2 
liver, kidney, 
intestines, pancreas, 
brain 
Glc, Gal, Fru, 
Man, GlcN PM  
I GLUT3 brain, testes Glc, Gal, Man, Xyl PM  
I GLUT4 adipose, muscle, small intesine, kidney Glc, GlcN I insulin 
II GLUT5 small intestine, kidney, brain Fru PM 
II GLUT7 intestines, testis, prostate Glc, Fru PM  
II GLUT9 
kidney, liver, small 
intestine, brain, 
placenta, lung, 
lymphoctyes 
Uric acid, Glc, 
Fru PM  
II GLUT11 heart, other muscle Glc, Fru PM  
III GLUT6 
brain, spleen and 
lymphoreticular 
system 
Glc, unknownd I stimulus unknown 
III 
 GLUT8 
testis, brain, adrenal 
gland, liver, spleen, 
brown fat, lung 
Glc, Fru, Gal, 
DHA I  
III GLUT10 
heart, lung, brain, liver, 
skeletal muscle, 
pancreas, placenta, 
kidney 
Glc, Gal PM  
III GLUT12 heart, prostate, skeletal muscle Glc I insulin 
III HMIT brain, adipose tissue myo-inositol PM  
  
a Adapted from Mueckler & Thorens, 2013, Purcell et al., 2011, Shepherd et al., 1992, Manolescu 
et al., 2007, Schmidt et al., 2009, Corpe et al., 2002, and this work  
bSubstrates are listed in order of preference by transporter if known. Abbreviations for substrates: 
DHA – dehydroascorbic acid (oxidized form of vitamin C); Fru – fructose; Gal – galactose; Glc – 
glucose; Man – mannose; GlcN - glucosamine 
cLocal: I - internal vesicles; PM – plasma membrane 
dcomplete kinetic parameters, including substrates other than glucose, are not known for GLUT6 
 
	  	  
9	  
in GLUT7 with a valine resulted in the loss of fructose transporting ability, with no effect 
on the ability to transport glucose (Manolescu et al., 2005). GLUT2, 5, 7, and 9 have this 
conserved isoleucine, and all lose fructose transporting ability when it is mutated to a 
valine (Manolescu et al., 2005; Manolescu et al., 2007). Non-fructose transporting 
GLUTs 1, 3, and 4 have a valine at this position.  
While the correlation of valine for glucose transport, and isoleucine for fructose 
transport holds true for class I and class II GLUT family members, it is not as straight-
forward in class III GLUT transporters. Additional analysis that included class III 
transporters found that a three amino acid domain comprised of aspartate-serine-valine 
(DSV) conferred fructose transporting ability to GLUT11. In the class I GLUT2, this 
motif is made of an asparagine-glycine-isoleucine (NGA) sequence. In class II GLUTs  
5, 7 and 9, this motif is an asparagine-alanine-isoleucine sequence. When GLUT11 has 
its DSV mutated to DSI, it loses its ability to transport fructose, with no loss of glucose 
transporting ability. When the native class III fructose-transporting conserved residues 
(DSV) are replaced with the class II fructose-transporters patch of conserved resides 
NAI, GLUT11 maintains fructose-transporting ability. Thus, it appears that the motif for 
determining fructose transport ability is hydrophobic and class specific (Fig 1.2).  
However, the determinants of substrate specificity must be even more nuanced 
because GLUT8, which can also transport fructose (Schmidt et al., 2009), has the 
residues NAV at the position of this “conserved” motif. This makes predicting the 
fructose-transporting abilities of an uncharacterized GLUT transporter difficult, as a  
 
	  	  
10	  
  
Fig 1.2 Motifs involved in fructose-transporting ability on GLUT transmembrane helix 7 
Figured modified from Manolescu, et al. 2007. A) GLUTs capable of transporting fructose are 
grouped according to the different motifs found at a conserved sequence on transmembrane 7 
(TM7) that determines substrate specificity. For comparison between substrate-determining 
motifs, other substrates are listed in order of preference. GLUT6 is a predicted fructose 
transporter.  
B) Model of TM7 (red) on GLUT7, and conserved isoleucine 314 thought to be important for 
substrate specificity, along with possible residues TM7 interacts with on TMs 1 and 2 (black).  
Class GLUT Helix-7 motif Substrates
I GLUT2 NGI Glc, Gal, Fru
II GLUT5 NAI Fru
II GLUT7 NAI (312-314) Glc, Fru
II GLUT9 NAI Uric acid, Glc, Fru
GLUT11 (mutant) NAI Glc, Fru
III GLUT11 (WT) DSV Glc, Fru
III GLUT8 NAV Glc, Fru, Gal, DHA
III GLUT6 TPI Glc, unknown
A 
B 
	  	  
11	  
 
conserved isoleucine alone on transmembrane helix 7, or the three resides of NGI 
(GLUT2), NAI (GLUTs 5, 7, 9) or DSV (GLUT11), or another patch such as NAV  
 (GLUT8), may confer fructose-transporting ability. With this in mind, GLUT6 is 
predicted to be have fructose-transporting activity based on the conserved isoleucine on 
transmembrane helix 7 that is seen in GLUTs 2, 5, 7, and 9, although its kinetic 
parameters are still uncharacterized. 
GLUT tissue expression and role in disease. The canonical sites of fructose 
metabolism are the small intestine, which expressed GLUTs 2, 5, and 8; liver, which 
expresses GLUTs 2 and 8; and kidneys, which express GLUT5. Dietary fructose is 
transported from the lumen of the gut by GLUT2 on the cell surface of the small 
intestine, and is then transported to the blood stream via GLUT5. As sugars are absorbed 
by the digestive tract and enter the hepatic portal, approximately 40-60% of dietary 
fructose is absorbed from the blood by the liver, expressing GLUT2, and kidneys, 
expressing GLUT5 (Douard & Ferraris, 2008).  
GLUT2. GLUT2 is a low affinity glucose and galactose transporter that also 
displays fructose-transporting abilities. It is expressed in hepatocytes, pancreatic β-islet 
cells, and the baso-lateral membranes of intestinal and renal epithelial cells (Mueckler & 
Thorens, 2013). GLUT2 deficiency leads to problems with glucose absorption by the 
intestines and liver, reabsorption by the kidneys, as well as proper glucose sensing by β-
islet cells. Furthermore, reduced GLUT2 expression or function can also impair glucose 
transport out of the liver, resulting in increased concentrations of intracellular glucose, 
and in turn, impairment of glycogen degradation, resulting in enhanced hypoglycemia 
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during fasting. Homozygosity for mutations resulting in non-functional GLUT2 proteins 
results in Fanconi-Bickel syndrome in patients, including a severe hyperglycemia in the 
fed state, hypoglycemia in the fasting state, a build-up of glycogen in both liver and renal 
cells, and severe glucosuria, due to the inability of renal cells to reabsorb glucose in the 
kidney.  
Heterozygosity for non-functional GLUT2 proteins is considered a risk factor for 
development of non-insulin dependent diabetes mellitus (Santer et al., 1997). Indeed, a 
common model of inducing diabetes in rodents is repeated injections of the glucose 
analog streptozotocin. Streptozotocin is selectively transported by GLUT2, and thereby 
selectively kills beta-islet cells expressing GLUT2, interrupting an appropriate glucose-
induced insulin response (Schnedl, 1994). GLUT2 protein levels can also be diminished 
by elevated levels of circulating free fatty acids, and the beta-oxidation of palmitic acid. 
Palmitic acid treatment in mice has been shown to interfere with the transcription factor 
IDX-1; this interference results in a decrease of Glut2 expression in β-islet cells 
(Gremlich, 1997). A hallmark of MBS and development of type II diabetes is an increase 
in circulating free fatty acids, and loss of GLUT2 may exacerbate the negative cascade of 
metabolic events. 
GLUT5. GLUT5 is the only fructose-transporter specific for fructose transport. It 
will not transport other hexoses or small molecules, implying that cells expressing Glut5 
have a way to metabolize fructose. Glut5 is expressed in intestine, kidney, brain, testes 
and sperm. It is also expressed at low levels in skeletal muscle (Douard & Ferraris, 2008).  
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Glut5 expression and GLUT5 transport activity are up-regulated by dietary 
fructose in the intestine (Jiang & Ferraris, 2001), and there are conflicting studies on 
whether it is also up-regulated by fructose in brain (Shu et al., 2006; Messier et al., 
2007). Whether fructose itself, or a metabolite of fructose metabolism, is the signal that 
induces this up-regulation is not known (Jiang & Ferraris, 2001). The up-regulation of 
Glut5 in response to dietary fructose may be due to the activity of the transcription factor 
carbohydrate response element binding protein (ChREBP), which is known to regulate 
other genes involved in fructose metabolism (Khk, AldoB), as well as genes in 
gluconeogenesis (Fbp1, G6pc), and fatty acid synthesis (Lpk, Acl, Acc1, Fas) (Iizuka et 
al., 2004; Koo et al., 2008). ChREBP activity is increased by high fructose diets (Koo et 
al., 2009). Glut5 expression and protein concentration is also up-regulated following 
ischemia, via the activity of hypoxia inducible factor 1α (HIF-1α) (Douard & Ferraris, 
2008). HIF-1α up-regulates AldoC in the brain following ischemia (Semenza et al., 1996; 
Jean et al., 2006), and controls the splicing of KHK isoforms from the low-fructose 
affinity isoform KHK-A to high-fructose affinity isoform KHK-C following ischemia in 
cardiac tissue (Mirtschink et al., 2015) (see Section 1.2.2). Given that GLUT5 levels are 
up-regulated along with other enzymes involved in fructolysis and lipogenesis in subjects 
exposed to high fructose diets via ChREBP activity, and elevation of GLUT5, KHK, and 
aldolase C levels by HIF-1α lead to cardiac hypertrophy with fructose exposure, this 
places the regulation of GLUT5 and its transport activity into two different aspects of 
metabolic syndrome, connecting it both to lipogenesis and cardiac stress when a high-
fructose diet is being consumed.  
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GLUT8. Interestingly, GLUT8 has been found to play a role in whole-body 
fructose metabolic regulation, since its global KO in mice increases fructose transport via 
the small intestine (DeBosch et al., 2012), and its liver-specific KO protects the liver 
against glucose intolerance, dyslipidemia, and macrosteatosis (DeBosch et al., 2013; 
Debosch et al., 2014). However, in the liver-specific KO of Glut8, while the liver is 
protected from these symptoms of metabolic syndrome, symptoms of metabolic 
syndrome are exacerbated in other organs of the body. Glut8 expression has been 
identified in a variety of tissues, including small intestine, liver, brain, and muscle, but 
the signal for its translocation to the plasma membrane has not been conclusively 
identified for tissues outside of the liver (Schmidt et al., 2009; DeBosch et al., 2012). It 
may be that GLUT8 transports fructose between internal compartments of the cell, or that 
the stimulus for its translocation is tissue-specific. Since GLUT8 has not been found on 
the plasma membrane in tissues outside of the liver and intestine (Lisinski et al., 2001; 
Schmidt et al., 2009), it is unlikely that GLUT8 transports fructose from the blood stream 
into these other organs.  
 GLUT9. GLUT9 has the ability to transport fructose, glucose, and uric acid 
(Anzai et al., 2008). Allele variations in the Glut9 gene have been associated with 
increased plasma uric acid levels and gout in (Doring et al., 2008), and increased serum 
acid levels have also been associated with cardiovascular disease risk, kidney failure, and 
metabolic syndrome. Excessive fructose metabolism can cause rises in uric acid 
production (Johnson et al., 2013) and it is curious that GLUT9 transports both fructose 
and uric acid.  
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 GLUTs 7 and 11. GLUT7 was originally identified in the small intestine, and is 
expressed at low levels in a variety of other tissues (Li et al., 2004). GLUT11 is found 
almost exclusively in muscle cells of all types, but at low levels (Gaster et al., 2004).  
 
1.2.2 Kinases capable of fructose phosphorylation 
Once fructose enters the cell, metabolism proceeds through either the phosphorylation 
product fructose 1-phosphate (Fru 1-P) or fructose 6-phosphate (Fru 6-P), depending on 
the activity of ketohexokinase (KHK) or hexokinase (HK), respectively. KHK is the 
hallmark enzyme specific for fructose metabolism, and will phosphorylate fructose at the 
C1-hydroxyl group, yielding Fru 1-P, which is then cleaved by aldolase into 
dihydroxyacetone phosphate (DHAP) and glyceraldehyde (Bais et al., 1985).  
 Ketohexokinase. KHK is a homodimer capable of phosphorylating 5-carbon ring 
hexoses. Fructose is the only physiologically relevant substrate; however, KHK has a Km 
of less than 2 mM for the rare sugars L-sorbose, D-tagatose, D-psicose, 2,5-anhydro-D-
mannitol, and 2,5-anhydro-D-mannose (Raushel & Cleland, 1973). Of these, sorbose, 
tagatose, and psicose will not be phosphorylated by HK, giving them potential 
applications in investigating KHK-specific metabolism. 
KHK has two different isozymes resulting from a splice variation at exon 3 
(Asipu et al., 2003), and splicing of one isozyme or the other is tissue-specific. KHK-C, 
also known as fructokinase, has a lower Km for fructose of about 0.8 mM, and is the 
splice-variant expressed in the liver. The ubiquitously expressed KHK-A has a higher Km 
for fructose, approximately 7 mM (Asipu et al., 2003). These two isozymes differ at exon 
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3, a 45 amino acid sequence where they differ at 32 of those positions (Fig 1.3). In tissues 
where one isozyme is found, it is at the exclusion of the other isozyme (Hayward & 
Bonthron, 1998). However, recent evidence suggests  cardiac tissue can switch from 
expressing the KHK-A isoform to KHK-C isoform under stress (Mirtschink et al., 2015).  
Khk mRNA splicing is under the control of splicing factor 3b subunit 1 (SF3B1), 
which is driven by HIF-1α activity, and by dietary fructose concentration. Hypoxia has 
been shown to cause a switch in splicing from the KHK-A isoform to the KHK-C 
isoform cardiac tissue. In heart, this switch can also be induced by fructose, and leads to 
cardiac enlargement after infarction, and exacerbates heart disease (Mirtschink et al., 
2015). It has yet to be determined whether fructose or hypoxia causes a switch in isoform 
splicing in other tissues, and what the consequences are. Additionally, serum uric acid 
levels have been shown to increase with dietary fructose in a KHK-dependent manner. 
Feeding of either fructose or D-tagatose, a C3 epimer of fructose, to healthy adult males 
resulted in an increase uric acid. Tagatose, which is not phosphorylated by HK, was able 
to increase uric acid levels 3 fold more than fructose was, illustrating this a phenomenon 
resulting from KHK activity (Buemann et al., 2000). Uric acid itself can stimulate KHK 
up-regulation (Lanaspa et al., 2012b), further compounding the negative biochemical 
cascade. If other tissues expressing KHK-A also undergo a splice conversion to KHK-C, 
this may lead to an increase in uric acid production, as seen in the liver and kidneys, or 
aberrant cell proliferation, as seen in the heart. 
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Fig 1.3 Ketohexokinase isoforms are structurally different surrounding the fructose-
binding site 
A) Alignment of amino acid sequence of mouse KHK exons 3A and 3C. Residues that differ 
between the two exons are shown in highlighted in blue (Hayward & Bonthron, 1998).  
B) The transparent surface of the co-complex (3Q92) with the fructose-binding site modeled in 
from 2HW1 (KHK-A; (Trinh et al., 2009)) is depicted. The residues from 72-115, which are 
encoded by exon 3c (and 3a in KHK-A) are colored blue. The ATP analog is a 
prymidionpyrimidine inhibitor (Maryanoff et al., 2012). Model compiled by D. R. Tolan and D. 
Salzberg. 
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Hexokinase. HK phosphorylates fructose at the C6-hydroxyl group, yielding Fru 
6-P, which can be phosphorylated by phosphofructokinase (PFK) to Fru 1,6-P2, and bring 
fructose into the glycolytic pathway. Glucose is the primary substrate for HK. HK-I is 
expressed in the brain, and ubiquitously throughout the body. HK-II is expressed in 
muscles, and HK-III is found in liver along with HK-IV. HK-IV, also known as 
glucokinase, is a low affinity glucose kinase and is important in glucose-sensing 
mechanisms in the liver and pancreatic β cells. HK-I, II, and III all have kinases that have 
Km values for glucose that are all below 1 mM (Table 1.3) and actively participate in 
glycolysis. Normal blood glucose levels are around 5 mM (Daly, 1998). The Km value for 
all HK isozymes for fructose is 1.6-3.5 mM, 10-fold higher than that of glucose (Stocchi 
et al., 1982). While physiological concentrations of fructose realized by different organs 
are currently unknown, it is clear that physiological concentrations of glucose would 
likely out-compete fructose binding to HK in vivo. 
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Table 1.3 Substrate affinities of hexokinase and ketohexokinase isoforms 
 
Kinase Tissue Distribution 
Glucose 
Km (mM) 
Fructose 
Km (mM) 
HK-Ia, b brain, ubiquitious .008-0.045 1.6-3.5 
HK-IIb, c muscle 0.23 3.5 
HK-IIIb, c liver 0.007 3.5 
HK-IVb, c 
(Glucokinase) pancreas, liver 10 2 
KHK-Cd 
liver, kidney, 
pancreatic β cells, 
small intestine 
NA 0.2-0.5 
KHK-Ad brain, ubiquitious NA 7 
 
aSols & Crane, 1954   
bSchimke & Grossbard, 1968  
cPurich et al., 1973  
dAsipu et al., 2003   
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1.2.3 Aldolase isozymes capable of cleaving phosphorylated fructose intermediates 
After phosphorylation of fructose by either KHK to Fru 1-P, or by HK to Fru 1,6-P2, 
fructose metabolism continues through cleavage by aldolase. The three aldolase isozymes 
A, B, and C differ in their tissue distribution and enzymatic efficiency toward Fru 1-P. 
While Fru 1-P is a substrate in vitro for all three isozymes, aldolase B (found in the liver 
and kidneys) has been referred to as Fru-1-P aldolase because its kcat/Km for Fru-1-P 
cleavage is 1.9 x 103 M-1 s-1. This is >100-fold greater than aldolase A, whose kcat/Km for 
Fru-1-P cleavage is 0.016 x 103 M-1 s-1. Aldolase C (found in the brain and smooth 
muscle) (Baron et al., 1995) has a kcat/Km for Fru-1-P cleavage of 0.18 x 103 M-1 s-1, 
making it 10-fold more effective than aldolase A at cleaving this substrate (Penhoet et al., 
1969b; Kusakabe et al., 1994; Pezza et al., 2003) (Table 1.4). While both aldolase A and 
C may participate in fructose metabolism, these different kinetics make aldolase C a more 
attractive candidate for metabolizing Fru 1-P in vivo.  
 
1.2.4 Enzymes involved in glyceraldehyde metabolism 
After Fru 1-P gets cleaved by aldolase, glyceraldehyde and DHAP are produced. DHAP 
is also one of the products following cleavage of Fru 1,6-P2, and can be isomerized by 
triose-phosphate isomerase (TIM) to G3P, which can enter the pool of free triose-
phosphates produced by glycolysis. Glyceraldehyde cannot enter this pool of glycolytic  
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Table 1.4 Aldolase isozyme kineticsa 
 
 
 Fru 1,6-P2 Fru 1-P 
Fru 1,6-P2 
/Fru 1-P 
Isozyme Km (µM) 
kcat /Km 
(µM-1s-1) 
Km 
(mM) 
kcat /Km 
(mM-1s-1) 
kcat /Km 
(10-3) 
Aldolase A 9.5 1.07 40 0.015 71 
Aldolase B 0.8 1.88 0.7 2 0.94 
Aldolase C 10.7 0.49 16 0.175 2.8 
 
a Compiled from Kusakabe et al., 1994, Penhoet et al., 1969a, and Pezza et al., 2003 
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intermediates until it is phosphorylated by triose kinase (DAK1) to G3P before entering 
glycolysis (Heinz et al., 1968). DAK participates in glyceraldehyde phosphorylation 
events outside of the Fru-1-P pathway for fructose metabolism, and there are other 
metabolic fates for glyceraldehyde other than being converted to G3P. In this way, DAK 
is associated with, but not specific for, the Fru-1-P metabolic pathway. Glyceraldehyde 
can also be converted to glycerol by alcohol dehydrogenase, and provide a precursor for 
lipogenesis. Fructose has the ability to stimulate alcohol metabolism (Jeffery & Jornvall, 
1983), and consuming both fructose and alcohol together may reinforce the shunt of 
metabolites towards glycerol formation and fat synthesis.  
 
1.3 Inborn Errors of Fructose Metabolism 
There are two inborn errors of metabolism associated with fructolysis: essential 
fructosuria (EF; OMIM #229800), caused by a deficiency of KHK, and hereditary 
fructose intolerance (HFI; OMIM #229600), caused by deficiency of aldolase B in the 
liver.  
 
1.3.1 Essential Fructosuria 
Patients with EF are asymptomatic. Historically, EF was diagnosed using Benedict’s 
reagent, which detects the presence of reducing sugars in the urine, but does not 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 In mammals, the enzyme that phosphorylates glyceraldehyde is annotated as triose kinase, 
while in yeast, where it was discovered, it is dihydroxyacetone kinase. Both proteins are 
abbreviated at DAK.  
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distinguish between aldoses and ketoses (Sachs et al., 1942). This test was routinely used 
to screen for diabetic patients, until it was replaced with the more specific glucose 
oxidase test, which specifically measures glucose concentrations. With the change in 
diagnostic testing, EF patients are no longer routinely diagnosed, although it is estimated 
that EF prevalence is on the order of other inborn errors of metabolism (Asipu et al., 
2003). 
 The physiological consequences of EF, or a possible drug-induced KHK 
deficiency, are that fructose does not get phosphorylated in the liver. Despite the dogma 
that the liver is the major site of fructose metabolism, most dietary fructose ingested by 
EF patients is eventually metabolized. Usually only 10-20% of ingested fructose is 
excreted, although excretion of fructose in urine is not constant, and is dependent on 
levels of fructose from diet (Bonthron et al., 1994; Asipu et al., 2003). Because EF is a 
benign condition, little investigation has been done to determine what mutations in Khk 
are common among EF patients, thus common mutations and their prevalence in the 
population are unknown. To date, only one family with EF has been molecularly 
characterized and found to be compound heterozygote for mutations Gly40Arg and 
Ala43Thr (Asipu et al., 2003). Cloning and expression of both of these mutations has 
revealed that Gly40Arg is a catalytically dead variant that disrupts activity of both KHK-
C and KHK-A isoforms. However, the Ala43Thr variant lowers thermostability, causing 
loss of enzymatic activity about 5 °C lower for both isozymes compared to WT protein. 
At physiological temperatures, this abolishes activity of KHK-C in the liver, but not 
KHK-A, which is a more thermostable protein. Thus, it is predicted that EF patients with 
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an Ala43Thr mutation would lose the ability to metabolize fructose in the liver, but 
maintain the ability to metabolize fructose in other organs.  
Studies on KO mice have been done to investigate the physiological 
consequences of loss of both isozymes, Khk-/-, or of KHK-A isozyme, Khk3a-/3a- while 
maintaining expression of KHK-C isozyme. Interestingly, the Khk3a-/3a- mouse develops 
markers of metabolic syndrome, including obesity, visceral fat accumulation, fatty liver, 
and elevated insulin and leptin levels, when fed a high fructose diet. WT mice fed a high 
fructose diet also exhibit these symptoms, but to a lesser extent. However, the Khk-/- 
mouse is protected from fructose-induced metabolic syndrome and shows no differences 
when compared to a WT mouse fed a normal diet (Ishimoto et al., 2012). This study not 
only shows that fructose is a causative agent of MBS in mice, it also points to a 
unappreciated role of KHK-A in whole body metabolism of fructose, since the absence of 
KHK-A causes a metabolic overload in the liver with deleterious consequences. It also 
highlights the need for investigation of other organs involved in fructose metabolism and 
the consequences that might befall individuals in a situation where KHK-A is active, but 
KHK-C is not, as with the Ala43Thr variant.  
 
1.3.2 Hereditary Fructose Intolerance 
The other, more detrimental, inborn error of fructose metabolism is hereditary fructose 
intolerance (HFI; OMIM #229600), which arises from a deficiency of aldolase B (EC 
4.1.2.13). Those afflicted with HFI experience liver and kidney dysfunction after fructose 
consumption, which can lead to death, particularly during infancy. The incidence rate of 
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HFI is as high as one in 20,000 live births, although it varies among ethnic populations 
(James et al., 1996; Santer et al., 2005; Gruchota et al., 2006; Coffee et al., 2009).  
HFI first presents in infancy after weaning when fructose-containing foods are 
introduced into the diet. Symptoms vary by patient after fructose ingestion, but infants 
often present clinically with failure to thrive, and persistent intake of fructose can lead to 
hypoglycemia, jaundice, NAFLD, renal tubular failure, metabolic acidosis, seizures, 
coma, progressive cirrhosis of the liver, and eventually death (Morris, 1968; Baerlocher 
et al., 1978; Laméire et al., 1978; Odièvre et al., 1978; Cox, 1993). The sequestration of 
intracellular phosphate in the unutilized intermediate, Fru 1-P, has been hypothesized as 
the causative agent of the pathophysiology in the livers of HFI patients (Van den Berghe, 
1978; Lanaspa et al., 2012a), although the complete biochemical underpinnings leading 
to hepatosteatosis are not well understood. Currently, the only treatment for HFI is to 
remove fructose from the diet. However, with the widespread use of fructose as a 
commercial sweetener, complete exclusion of fructose is difficult, and daily perils remain 
for fructose-intolerant individuals (Ali et al., 1993). Additionally, long-term 
consequences in the liver and other organs metabolizing fructose of HFI patients exposed 
to low doses of fructose are not known. An animal model for HFI would enable the study 
of the disease pathology and its long-term consequences. 
  
1.4 Aims of Dissertation 
The contribution of dietary fructose to different states of metabolic dysregulation in diets 
of humans is controversial. Studies using human cohorts have often compared patient 
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volunteers who are already obese or have diabetes, or both, and make it hard to compare 
across trial groups. While the biochemical consequences of high fructose loads in 
experimental animal models are becoming increasing more clear (Nakagawa et al., 2006, 
Lim et al., 2010, Johnson et al., 2007), these experiments have usually compared the 
metabolism of rodents given synthesized diets with exposure to fructose concentrations 
that do not reflect daily human eating patterns.  
Since high-fat diets can also lead to obesity and NAFLD or other fat-storage 
symptoms, it is important, but often difficult, to separate the contribution of different 
dietary components towards the development of these symptoms. Additionally, while it is 
clear that fructose contributes to MBS in humans and rodents, there are multiple 
pathways that lead to cell and tissue damage, and these pathways interact and sometimes 
enhance each other. The need for well-controlled experiments with many subjects is 
obvious, and not achievable with human volunteers alone. However, in order to draw 
proper conclusions from experiments using animals, it is important that the animal 
recapitulates the condition seen in human patients.  
 The first aim of this thesis is to characterize a novel mouse model of HFI 
generated by a complete KO of the Aldo2 gene. The anatomical manifestations of HFI are 
similar to those in MBS, such as the build up of fat and scar tissue in the liver damage as 
seen in NAFLD, and more research is needed to find the biochemical similarities and/or 
differences between the development of HFI and MBS. Additionally, studies of EF, HFI, 
and MBS are lacking a whole-body understanding of fructose metabolism; therefore a 
validated animal model is needed. Furthermore, extrapolation from mouse studies to 
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human conditions requires establishment that fructose metabolism in such an animal is 
similar to that in humans. Study of genetic diseases in both organisms is important for 
extending this correlation. HFI symptoms overlap with MBS symptoms in humans, but 
they appear in a much shorter time frame with lower doses of fructose. Therefore, the 
biochemical mechanisms leading to liver damage in HFI patients may apply to 
understanding the biochemical mechanisms leading to liver damage in MBS patients. A 
mouse model of HFI can also be used to validate that fructose metabolism between mice 
and humans are similar. HFI patients have a clearly defined phenotype, and a mouse that 
phenocopies the HFI symptoms after loss of aldolase B activity would be useful for 
identifying similarities and differences in fructose metabolism by the livers of these two 
species. 
Here, the creation of a mouse model for HFI is described by targeting the Aldo2 
gene. The Aldo2-/--homozygous mice were tested for their ability to serve as a model for 
HFI by measuring mortality, liver enzyme activities, and liver histology following 
exposure to fructose. The failure to thrive phenotype and liver pathology of these mice 
were completely consistent with observations in humans with HFI. This animal should 
provide a valuable resource for answering remaining questions about fructose metabolism 
in HFI, as well as investigation of the biochemical mechanisms that lead to fatty liver and 
cirrhosis associated with MBS (Baerlocher et al., 1971; Steinmann et al., 2001; Johnson 
et al., 2013).  
The second aim of this thesis is to identify organs outside the liver that participate 
in fructose metabolism. In the light of the growing epidemic of obesity and MBS, and the 
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negative and varied consequences to tissues participating in this metabolism, identifying 
all organs capable of fructose metabolism is essential to understanding physiological 
regulation of whole-body fructose metabolism in health and disease. GLUT5 and KHK 
are specific to fructolysis; other fructose-transporting GLUTS (including GLUTs 2, 7, 8, 
9, and 11; and the prediction of GLUT6), aldolase, and triose kinase all participate in 
fructolysis. Accordingly, any tissue expressing a Glut gene capable of constitutive 
fructose transport from the blood stream (Glut2, 5, 7, 9, or 11), KHK (Khk), and aldolase 
B or C (AldoB or AldoC) should be capable of metabolizing fructose via a fructose-
specific, Fru-1-P pathway. Tissues in human outside of the liver and kidney predicted to 
be capable of fructose metabolism were identified by bioinformatic analysis using the 
VNB (Funari et al., 2010). This analysis revealed significant expression of genes 
necessary for fructose metabolism in the brain. In situ hybridization of mouse brain 
slices, along with measurements of specific activity of the enzymes KHK and aldolase, 
confirmed the expression of these proteins. Measurement of hexose oxidation rates of 
dissected brain tissue was used to investigate the rate of fructose metabolism, and the 
contribution of KHK versus HK, to this metabolism in the brain. 
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CHAPTER TWO: Materials and Methods1 
2.1 Generation and Maintenance of Mouse Colony  
2.1.1 Care and use of animals  
Animal care was performed in accordance with institutional guidelines. All protocols 
were approved by the Boston University, Institutional Animal Care and Use Committee. 
Mice were kept on normal chow diets (LabDiet, St. Louis, MO; formula 5P75), unless 
they were being exposed to fructose (Protocol 12-030). Mice used for experiments were 
weighed every two or three days after weaning, until sacrificed. 
 
2.1.2 Fructose exposure of mice 
Mice were maintained under normal conditions, and fed either fructose-free chow (Bio-
Serv, Flemington, NJ; formula #F6700 with 200 g/kg casein, 3 g/kg L-cystine, 129.5 g/kg 
corn starch, 500 g/kg dextrose, 50 g/kg cellulose, 70 g/kg soybean oil, 35 g/kg AIN-93G 
mineral mix, 10 g/kg AIN-93 vitamin mix, 2.5 g/kg choline bitartrate, 0.0014 tert-
butylhydroquinone) with access to either water, or a 40% (w/v) fructose drinking 
solution. Length of fructose exposure varied by experiment. After termination of 
experiments, mice were sacrificed, and livers and brains were harvested on ice.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Many of the following procedures are expanded on methods that have been published 
previously, in the papers by Oppelt, Coffee, and Tolan, “Aldolase-B knockout in mice 
phenocopies Hereditary Fructose Intolerance in Humans” (2015) (Oppelt, S.A., Sennott, E.M. and 
Tolan, D.R. (2015). Aldolase-B knockout in mice phenocopies hereditary fructose intolerance in 
humans. Molecular Genetics and Metabolism 114: 445-550.), and Oppelt, Zhang, and Tolan, 
“Specific regions of the brain are capable of fructose metabolism” (submitted).  	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2.1.3 Generation of Aldo2-/- knockout mouse model  
The embryonic stem (ES) cells containing a null mutation in the aldolase-B gene (Aldo2) 
(Aldob_AA6, BA9, and BF10) were obtained from the KOMP Repository (University of 
California, Davis, KnockOut Mouse Project). The null mutation was created by deleting 
the open reading frame of the Aldo2 gene from the middle of exon 2 through the middle 
of exon 9, and inserting a lacZ reporter gene and a neomycin cassette, flanked by loxP 
sequences. Generation of the Aldo2-/- mouse was contracted out to the Transgenic Core 
Facility at Brigham & Women’s Hospital of Harvard Medical School (Dr. Arlene Sharpe, 
Director). Each of the KOMP ES-cell clones was expanded, tested for euploidy (81-90, 
61-70, and 71-80%, respectively), and genomic DNA was isolated to confirm that Aldo2 
had been targeted by PCR-mediated genotyping using the forward primer SU2 and the 
reverse primers TUR2 or LacInZRev for detection of WT or KO alleles, respectively (see 
Section 2.2.2). Targeted ES cells were implanted into C57BL/6NTac (albino) blastocysts. 
Pups were evaluated for chimeric coat color as a read-out for targeted ES cell integration, 
and male pups with 75-90% black coat were bred to C57BL/6NTac (albino) females. F1 
generation of pups from the chimeric male-albino female mating were checked for a 
black coat color, representing successful germline transmission of the ES cells. Less than 
3 cm of tail was cut from F1 pups at weaning, DNA was extracted from tail snips, and the 
genotype was determined with a PCR-mediated genotyping scheme (see Sections 2.2.1 
and 2.2.2).  
	  	  
31	  
 
2.2 Molecular Genetic Techniques 
2.2.1 DNA extraction from mouse tail snips  
Tails were snipped at weaning and incubated in 200 µl extraction buffer (Viagen) 
(without Proteinase K) at 55 °C overnight, then at 85 °C for 30-60 min. This DNA (1-5 
µL) was used directly without further extraction for the PCR.  
 
2.2.2 Polymerase Chain Reaction (PCR) 
PCR was performed with either 1-5 µL of genomic DNA obtained from mice tail snips, 
or 5 ng of plasmid template, with 1 µM of each forward and reverse primers (Table 2.1), 
in 25 µl final volume with 200 µM of each deoxynucleotide triphosphates, 20 mM Tris-
HCl (pH 8.9), 22 mM ammonium acetate, 22 mM KCl, 5% (v/v) glycerol, 0.05% (v/v) 
each Tween-20 and NP-40, 2.5 mM MgCl2, and Taq DNA polymerase (0.025 U/mL). 
Cycling conditions for genotyping of mouse tails were as follows: 94 °C for 5 min; (60 
°C for 1 min; 72 °C for 1.5 min; 94 °C for 0.5 min) repeated 35 cycles; 72 °C for 10 min; 
hold at 4 °C.  
 
2.2.3 Creation of dioxygenin-labeled RNA probes 
All work was done under RNAse-free conditions. RNA probes were generated using the 
DIG nucleic acid detection kit from Boehringer Mannheim Biochemical (Indianapolis, 
IN) according to manufacturer’s instructions. The appropriate RNA polymerase (SP6, T7 
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or T3) (Ambion) was used to generate RNA probes from template cDNA plasmids 
containing the mouse Glut5 (GenBank ID: AI786845), Glut6 (BC058210), Glut9 
(BC018897), Khk (AI256253), AldoC (AI180787), or Dak (triosekinase, BC021917) 
(cDNAs attained vendor). Probe concentration was determined by allele-specific 
oligonucleotide (ASO) hybridization blot quantification using the Boerhinger Genius 
System and dioxygenin (DIG)-labeled control RNA (Roche). ASO hybridization blots 
were preformed as described (Coffee, 2010). 
 
2.2.4 Agarose gel electrophoresis of DNA 
DNA samples were mixed with loading buffer (0.04% (w/v) xylene cyanol FF, 15% 
(w/v) Ficoll, 1% (w/v) SDS) at a 5:1 ratio, and loaded into wells of 1-1.5% (w/v) TAE 
(40 mM Tris, pH 8.1, 20 mM acetate, 1 mM EDTA) agarose gels. Gels were 
electrophoresed at 80-110 mV for an appropriate amount of time, and then stained by 
immersion in 0.5 µg/mL of ethidium bromide for 10-15 min. Gels were destained for 10 
min in dH2O, and visualized using a Gel Doc imaging system (Bio-Rad). DNA size and 
concentration was measured by comparing band running distance and intensity, 
respectively, to an aliquot of known DNA standard run on the same gel (Hi-Lo DNA 
Marker, Minnesota Molecular Inc.). 
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Table 2.1 Primers used in PCR genotyping  	  
Primer Sequence 5ʼ-3ʼ Binding Sitea Orientation 
LacInZRev GTCTGTCCTAGCTTCCTCACTG lacZ reverse 
SU2 GGTGGTAGTCATGGCCATTTGG mouse aldoB intron 1 (4188) forward 
TUR2 GCTTTTCCCTATATGCATCCTG CAGGATGCATATAGGGAAAAGC 
mouse Aldo2 
intron 2 (5194) reverse 
TUR2V GCGTTTCCCTATATGCATCCTG
b 
CAGGATGCATATAGGGAAAAGC 
mouse Aldo2 
intron 2 (5194 reverse 
 
aThe number in parenthesis is the position number to which the 5ʼ-base of each primer 
corresponds in the NCBI RefSeq for the Aldo2 gene from M. musculus C57BL/6J 
(chromosome 4) (NC_000070.6). 
bThe underlined difference between TUR2V and TUR2 correspond to differences in the 
sequence between SV-129 (NCBI AH_011101) and C57BL/6J, respectively. 
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2.2.5 DNA purification with agarose or glass milk 
For extraction of DNA from agarose gels, 0.8% (w/v) low-melt agarose gel was used, and 
the DNA was extracted using either a NucleoSpin Extract II column (Macherey-Nagel) 
after melting at 55 °C for 10 min as per manufacturer’s instructions, or glass milk.  
DNA can also be purified using a slurry of finely ground amorphous silica 
particles, called “glass milk”. For glass milk purification, DNA was purified from 0.8% 
low-melt agarose gels by adding 3 gel volumes of 6 M sodium iodide to the melted 
agarose gel slice. An aliquot of 5 µl of glass milk (prepared as a 50% (w/v) slurry 
dissolved in H2O) was added to the dissolved DNA sample and incubated for 10 min, 
mixing every 1 min. After brief centrifugation, the pellet was resuspended in 0.5 mL of 
50% (v/v) EtOH in 50 mM NaCl, 10 mM Tris, pH 7.5, 2.5 mM EDTA, pH 8.0, and then 
centrifuged and washed more extensively. The DNA was dried to remove ethanol and 
dissolved in 10 mM Tris, 1 mM EDTA, pH 7-8. DNA concentration after glass milk 
purification was determined by agarose gel electrophoresis as described above. 
 
 
2.3 Collection of Tissues and Histological Staining 
2.3.1 Tissue collection and dissections 
All mice that did not expire during an experiment were sacrificed by either cervical 
dislocation, or CO2 asphyxiation, with cervical dislocation as a secondary procedure to 
confirm death. After confirmation of death, mice were sprayed with 70% EtOH to mat 
down fur, and mice were cut open on ice. Livers were dissected out through a cut made to 
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the midsection of animals. Brains were dissected out by making a cut on the back of the 
neck, and then down the midline of the head to remove skin from the skull. Skulls were 
separated from the spinal cord, and also cut down the midline along the top of the skull, 
to the nasal cavity. Incisions were made from the base of the skull towards the eye cavity 
approximately one-third down either side, so that skull pieces could be removed and the 
brain could be exposed. Once the skull was removed from over the top of the brain, care 
was taken to gently remove the brain as an entire structure, including the olfactory bulb 
and cerebellum, out of the bottom of the skull and onto a glass plate, kept on ice. The 
cerebellum, hippocampus, olfactory bulb, and front one half of the cortex were dissected 
away from the rest of the brain.  
 
2.3.2 Tissue sectioning  
All experiments were carried out in accordance with the EC Directive 86/609/EEC for 
animal experiments. The brains of adult male mice perfused with 10% (v/v) 
paraformaldehyde were dissected on ice and stored at 4 °C in phosphate-buffered saline 
(PBS) containing 30% (w/v) sucrose and 0.1% (v/v) diethylpyrocarbonate. Brain tissues 
were mounted using Tissue-Tek O.C.T. compound (Sakura) at –20 °C and coronal 
sections (14 µm) were prepared using a Cryocut 1800 cryostat. Tissue sections were 
collected on Gold Seal Micro slides, placed inside a slide box, desiccated for 30 min 
under a vacuum, and stored at –80 °C. 
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2.3.3 RNA in situ hybridization of tissue slices  
In situ hybridization (ISH) of brain tissue slices were performed essentially as described 
previously (Funari et al., 2005). Sections were probed with anti-sense probes to detect 
gene expression, and with sense probes as a negative control. Briefly, cryo sections were 
rehydrated by washing in decreasing concentrations of ethanol (100%, 95%, 70%, and 
50%) and then in 2X SSC. Rehydrated tissues were digested with proteinase K (10 
µg/mL) in 0.1 M TEA, pH 8.0, at 37 °C for 30 min, then transferred to 28 mM acetic 
anhydride in the same buffer and incubated at 37 °C for 10 min. After rinsing with 2X 
SSC, the sections were dehydrated in increasing concentrations of ethanol (50%, 75%, 
90%, 100%). DIG-labeled RNA probes (2 ng/µL) (see Section 2.2.3) were incubated at 
68 °C for 10 min and cooled on ice before diluting (1:25) in hybridization buffer with a 
final concentrations of 1.4 mM Tris-HCl, pH 7.5, 42 mM NaCl, 28 µM EDTA, 53% (v/v) 
deionized formamide, 10% (v/v) dextran sulfate, and 1.3% (v/v) Blocking Reagent 
(Roche). This hybridization solution was sealed over the sections with DPX Mountant 
(Fluka), and incubated at 55 °C for 18-36 h. Slides were unsealed and washed in 2X SSC 
at 55 °C for 30 min, in 2X SSC, 50% (v/v) formamide at 55 °C for 30 min, and finally 
twice in 2X SSC at 37 °C. Slides were treated with RNase A (20 µg/mL in 0.5 M NaCl, 1 
mM EDTA, 10 mM Tris-HCl, pH 7.5) at 37 °C for 30 min, and washed with buffer only 
at 55 °C for 30 min. Visualization using DIG-antibody (1:1000) (Roche) was performed 
according to the manufacturers instructions. Following color development, glycerol was 
applied to the tissue sections and they were mounted with coverslips and sealed with nail 
polish. Dried slides were stored at 4 °C in the dark. 
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2.3.4 Hemotoxylin and eosin (H&E) staining  
H&E and Oil Red O stains were preformed at Massachusetts General Hospital Cancer 
Center, Charlestown, MA. Tissue was either fixed in 10% paraformaldehyde or 
immediately frozen, embedded in paraffin, and sectioned. Briefly, for H&E staining, 
slides were deparaffinezed, rehydrated, then stained in hematoxylin and counterstained in 
eosin, followed by dehydration. Staining was visualized under light microscope. H&E 
stains acid macromolecules, such as DNA or RNA.  
 
2.3.5 Oil Red O staining 
Fresh tissue was frozen, sectioned, fixed in formalin, rinsed with isopropanol, and stained 
with freshly prepared Oil Red O (Sheehan & Hrapchak, 1980). Following an additional 
rinse with isopropanol, slides were stained with hematoxylin and rinsed. Staining was 
visualized under light microscopy. Oil Red O binds lipid droplets inside the cell.  
 
2.3.6 Microscopy of slides 
All ISH, H&E, and Oil Red O slides were visualized under light microscopy at 10X and 
20X objectives, and pictures were taken on an Olympus 1X70 microscope using an 
attached Olympus camera (Model BH2-RFL-T3) and Pictureframe software.  
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2.4 Detection of Protein and Metabolic Activity in Tissues 
2.4.1 Preparation of cell lysis fraction of dissected tissues 
Liver and brains were either dissected and used immediately for assays, or were stored at 
-80 °C for use in later assays. Brains were dissected into subregions, and the olfactory 
bulb, cortex, hippocampus, and cerebellum were combined to create a “fructose 1-P 
positive region” (Fig 2.1). Fragments (60-120 µg) of dissected liver, or brain samples, 
were weighed in 1.5 mL eppendorf tubes, and 1 vol of native lysis buffer (150 mM NaCl, 
20 mM HEPES, pH 7.4, 1 mM EDTA, 1% (v/v) Triton X100) was added to samples. 
Tissues subjected to sonication at high setting for 12 30s cycles in a Bioruptor Twin bath 
sonicator. The sonicate was centrifuged for 60 min at 20,000 g at 4 °C. Supernatant 
fractions were separated from the pellet fraction. 
 
2.4.2 Preparation of membrane fraction of dissected tissues 
From sonicated tissue samples, the pellet was used to create a membrane fraction for 
detection of membrane-bound proteins. The pellets were solubilized in 1% SDS and 
boiling for 5 min. Solubilized pellet samples were clarified by centrifugation at 20,000g 
for 10 min at 4 °C. Final volumes varied depending on the original pellet size, and ranged 
from 80-150 µL. The supernatant was taken as the membrane-bound protein fraction.  
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Fig 2.1 Brain regions with highest proportion of cells expressing genes in Fru-1-P pathway 
Schematic of brain regions of a mouse brain, adapted from Fernandez & Torres-Aleman, 2012. 
Regions dissected out are marked with arrows, and either kept separate, or combined to make a 
Fru-1-P positive brain sample.  
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2.4.3 Determination of protein concentration by Bradford assay 
Protein concentrations were determined by a Coomassie dye-binding assay (Bradford, 
1976). The assays were either preformed in a cuvette (final vol 1 mL) or a 96 well plate 
(final vol 250 µL), by combining 50 µL protein sample of appropriate dilution with either 
980 µL or 200 µL, respectively, of Bradford reagent (0.01% Coomassie Brilliant Blue G-
250, 4.7% EtOH, 8.5% phosphoric acid). Samples were incubated for 3-5 min at room 
temperature (RT), and absorbance read at 595 nm. Protein concentration was calculated 
from an equation derived from a standard curve (2-15 µg) with known concentrations of 
bovine serum albumin (BSA). Due to interference by SDS, 1% SDS was added to 
standard curves to calculate protein concentration in membrane fraction of sonicated 
tissue samples.  
 
2.4.4 Enzymatic activity assays  
Activity of hexokinase (HK), ketohexokinase (KHK), aldolase (both Fru 1,6-P2 and Fru 
1-P), and fructose-1,6-bisphosphotase (FBPase) used coupled assays based on oxidation 
or reduction of NAD(P)H, represented by schematics shown in Figs 2.1-2.4. Assays were 
started by combining 200 µL of activity cocktail to 50 µL of protein sample, at an 
appropriate dilution. Dilutions of sample were chosen that gave a rate of ΔA340/min of 
0.005 to 0.025, and absorbance was measured over 30 min. 	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2.4.5 SDS-PAGE gel electrophoresis 
Protein samples were separated by electrophoresis using a discontinuous gel system, 
consisting of a stacking gel (top layer) and a resolving gel (bottom layer) (Laemmli 
1970). The stacking gel consisted of 5% (w/v) acrylamide/bisacrylamide (29:1 ratio), 125 
mM Tris, pH 6.8, 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulfate and 0.04% (v/v) 
TEMED. The resolving gel consisted of 12% (w/v) acrylaminde:bisacrylamide (29:1), 
375 mM Tris, pH 8.8, 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulfate, and 0.06% 
(v/v) TEMED.  
Protein samples were prepared for electrophoresis by combining with gel loading 
buffer (250 mM Tris, pH 6.8, 10% (w/v) SDS, 0.5% (w/v) bromophenol blue, 50% (v/v) 
glycerol, and 715 mM β-mercaptoethanol) at a 5:1 ratio with a total volume of 20 µL, 
heated at 95 °C for 5 min, then applied to gel wells. Kaleidoscope or broad range protein 
marker (Broad Range Molecular Weight Marker, Bio-Rad, Hercules CA) containing 
myosin (200 kD), β-galactosidease (116 kD), phosphorylase b (97.4 kD), serum albumin 
(66.2 kD), ovalbumin (45 kD), carbonic anhydrase (31 kD), trypsin inhibitor (21.5 kD0, 
lysozyme (14.4 kD), and aprontinin (6.5kD), were included according to manufactorer’s 
instructions. Gels were electrophoresed for 35 min at 75 mV to move samples through 
the stacking gel, and then at 200 mV until dye ran off gel, as samples moved through the 
resolving gel.  
Gels were then either prepared for Western Blotting, or were immediately 
visualized by staining with a 0.25% (w/v) Coomassie Brilliant Blue R-250 stain in 5:5:1 
(v/v) dH2O:methanol:acetic acid. Stained gels were destained in the same solvent.  
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Fig 2.2 Schematic of hexokinase coupled activity assay  
Hexokinase (HK) assays were performed in a buffer with a final concentration of 100 mM Tris, pH 
8, 10 mM MgCl2, 0.5 mM EDTA, 200 µM NADP+, 10 mM ATP, 0.1 U/µL glucose-6-phosphate 
dehydrogenase (G6PDH), with final substrate concentration of 2 mM glucose, and an increase in 
ΔA340/min was measured. 
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Fig 2.3 Schematic of ketohexokinase coupled activity assay  
Ketohexokinase (KHK) assays were performed in a buffer with a final concentration of 33 mM 
TEA, pH 8, 20 mM MgCl2, 100 mM KCl, 200 µM NADH, 1.35 mM phosphoenolpyruvate (PEP), 1 
mM ATP, 5 U/mL of pyruvate kinase, and 5 U/mL of lactate dehydrogenase (LDH), with a final 
substrate concentration of 8 mM fructose, and a decrease in ΔA340/min was measured.  
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Fig 2.4 Schematic of aldolase coupled activity assay   
Aldolase assays were in a buffer with a final concentration of 50 mM TEA, pH 7.4, 10 mM EDTA, 
0.15 mM NADH, 1.2 U/mL glycerol-3-phosphate dehydrogenase (GDH) and triose phosphate 
isomerase (TIM) mixture (10:1 w/w; Sigma), with either 2 mM for Fru 1,6-P2 as substrate, or 25 
mM using Fru 1-P as substrate. A decrease in ΔA340/min was measured. 
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Fig 2.5 Schematic of fructose-bisphosphatase activity assay  
Frucotse bisphosphatase (FBPase) assays were in a buffer with a final concentration of 28 mM 
HEPES, pH 7.4, 2.5 mM MgCl2, 1 mM DTT, 550 mM NADP+, 9 U/mL glucose 6-phosphate 
dehydrogenase (G6PDH), 12 U/mL lactate (LDH), 100 µM EDTA, 0.85% (v/v) ammonium sulfate, 
with a final concentration of 3 mM Fru 1,6-P2 as substrate. A decrease in ΔA340/min was 
measured.  
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2.4.6 Western blotting for membrane fraction proteins 
Protein from either lysate or membrane fraction samples of sonicated tissue preps was 
separated by SDS-PAGE. Gels and Protean Extra Thick Blotting Paper (BioRad) were 
incubated with in Towbin buffer (250 mM Tris base, 192 mM glycine, 20% MeOH) for 
15 min. PVDF membranes were submerged and incubated in 100% MeOH for 3 min. 
Protein from the SDS-PAGE gel was transferred to the PVDF membrane between two 
saturated pieces of blotting paper using a semi-dry transfer cell (SpectraMax 190) at 18-
20 mA for 40-45 min. Non-specific protein binding was blocked by incubating 
membranes in a solution of TBST (1X Tris-buffered saline, pH 7.4, 0.1 % (v/v) Tween 
20/20) with a blocking agent (Table 2.2), for 3 h at 25 °C, or overnight at 4 °C. 
Membranes were then incubated in a solution containing primary antibody at the 
appropriate dilution in TBST (Table 2.2) for 3 h at 25 °C, or overnight at 4 °C, then 
rinsed 3 times for 5 min each in TBST. Appropriate primary antibody dilutions were 
determined by testing concentration gradients of each antibody against a tissue sample, 
using four to five dilutions in a range suggested by manufacturer.  
After rinsing off excess primary antibody, membranes were incubated in TBST 
with 5% milk, 2% BSA, and appropriate secondary antibodies conjugated to horseradish 
peroxidase (HRP) for 1 h at 25 °C. Membranes were rinsed of excess secondary antibody 
3 times for 10 min each rinse in TBST, and 2 times for 20 min each in TBS to remove 
detergent. Proteins recognized by the appropriate primary antibodies were visualized 
using SuperSignal West Dura Extended Duration Substrate (Thermo Scientific)  
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Table 2.2 Antibodies used in Western blotting 
Antibody Isotype 
Blocking 
Solution Dilution Vendor, Cat# 
GLUT2 rabbit IgG 5% milk, 1% NGS 1:1000 Santa Cruz, H-67 
GLUT3 goat IgG 5% milk, 1% NGS 1:50 Santa Cruz, I-14 
GLUT5 rabbit IgG 5% milk, 1% NGS 1:5000 Santa Cruz, H-200 
GLUT6 rabbit IgG 5% milk, 1% NGS 1:1000 Santa Cruz, M-125 
GLUT9 rabbit IgG 5% milk 1:5000 Novus, NBP1-05054 
Α1 Na+/K+ ATPase  mouse IgG1 1% NGS 1:200 Abcam, AB7671 
HRP-conjugated  
α-rabbit IGg goat IgG 5% milk, 2% BSA 1:3000 
Bio-Rad, 
1662408EDU 
HRP-conjugated  
α -goat IGg rabbit IgG 5% milk, 2% BSA 1:3000 
Millipore, 
AP106P 
HRP-conjugated  
α-mouse IGg goat IgG 5% milk, 2% BSA 1:3000 
Abcam, 
AB6789 	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according to manufacturer’s instructions. Briefly, a 1:1 mixture of the two SuperSignal 
West substrate solutions was applied evenly to membranes. HRP converts the substrate to 
produce chemiluminescence. Blots were visualized by autoradiography by exposing to x-
ray film for 1 to 180 s, as appropriate, and developed using KODAK M-35A X-Omat 
Processor.  
 
2.4.7 Determining oxidation rates of hexoses by tissues 
Tissues were dissected from adult mice following cervical dislocation, immediately 
chilled on ice, and weighed. Weighed tissues (30–140 mg) were placed into airtight 
“Warburg” flasks containing a glass-blown center well (G. Finkenbeiner Inc. Waltham, 
MA), into which a 2 N KOH-saturated fluted Whatman 1 filter paper was placed. 1.5 mL 
of ice-cold phosphate-buffered saline (PBS) containing [U-14C]-hexose (specific 
radioactivity 0.06–0.15 mCi/mmol) was added to the tissue. The flasks were incubated in 
a shaking incubator for 60 min at 37 °C, HCl was added to a final concentration of 0.6 N 
to stop reactions, and tissues were incubated for 15 min to drive out any remaining CO2 
trapped in tissues. The contents of the center well were collected for liquid scintillation 
counting by rinsing with 200 µL additional PBS. Counts from reactions where 0.6 N HCl 
was added at time zero were taken as background levels of radiation, and subtracted from 
final counts of remaining reactions. From the 14CO2 released and the specific 
radioactivity of the hexose, the µmol CO2/h/g wet weight of tissue was calculated using 
the following equation:  
	  	  
49	  
 
((Final radioactive counts / 2.22 x 106 / specific radioactivity µCi/mM) x 6) / wet weight  
 
where 2.22 x 106 is the conversion factor between dpm and µCi, and 6 is the number of 
moles CO2 produced per mole hexose.  
 
2.5 Bioinformatics and Statistics 
2.5.1 In silico expression profiling using a Virtual Northern Blot program (VNB) 
VNB program was used as described previously (Funari et al., 2010). Briefly, ClustalW 
alignments of human cDNA sequences from RefSeq 
(http://www.ncbi.nlm.nih.gov/RefSeq/) for each gene in the Fru-1P pathway, and its 
known homologs, were input into the VNB to generate gene-specific probes. GLUT 
homologs included the genes encoding human GLUT1 through GLUT13 (NM 006516, 
NM 00340, NM 006931; NM 001042, NM 001135585, NM 017585, NM 207420, NM 
014580, NM 001001290, NM 030777.3, NM 030807.3, NM 145176.2, NM 052885.3, 
respectively); aldolase homologs included all three isozymes, A, B, and C (NM 000034, 
NM 000035, NM 005165, respectively). KHK (NM 000221) isozymes are generated by 
alternative splicing from one gene (Hayward & Bonthron, 1998); DAK (NM 015533) 
does not have isozymes. VNB generated alignments against the genome for these 
sequences. Parameters of 20-base probe size and 8 base window size were used. VNB 
program collected expressed sequence tags (ESTs) from a Basic Local Alignment Search 
Tool (BLAST) search of dbEST (http://www.ncbi.nlm.nih.gov/dbEST) that exactly 
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matched the gene-specific probes generated from the alignment, which were 
subsequently mapped to an EST library using annotation from Entrez. Finally, these 
identities were used to search library construction information in the Cancer Genome 
Anatomy Project (CGAP) database (http://cgap.nci.nih.gov/). Summing ESTs from 
similar tissues tabulated results; ESTs from cell lines, tumor, or disease-derived tissues 
were not included in this analysis. Summing all EST “hits” for similar tissues generated a 
qualitative profile of gene expression. Summing all EST “hits” from un-manipulated or 
otherwise not “normalized” libraries for similar tissues generated a quantitative profile of 
gene expression. The denominators for the total ESTs from all libraries for each tissue 
were derived from CGAP. 
 
2.5.2 Statistics  
An ANOVA test was used to compare statistical significance among groups of three or 
more measurements. A Student’s t-test was used to compare significance between pairs 
of measurements. 
For assays that were performed in triplicate during a single trial, mean and 
standard deviation were calculated. One standard deviation was used for error reporting. 
For assays that were run in duplicate or triplicate during a trial, and multiple trials were 
performed at different times, the mean of each trial was calculated, and the standard error 
of the means was used for error reporting. 
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CHAPTER THREE: The AldoB knockout mouse is an appropriate animal model 
for Hereditary Fructose Intolerance2 
 
A key to understanding any type of metabolism comes from study of disease 
states that affect such metabolism. Ketohexokinase (KHK) is the flagship enzyme in the 
fructose-specific metabolic pathway. In those with the benign condition called essential 
fructosuria (EF; OMIM #229800), a loss of KHK activity forces eventual metabolism of 
ingested fructose by unclear alternative pathways (Steinmann et al., 2001). A more 
serious defect in fructose metabolism is the autosomal recessive condition hereditary 
fructose intolerance (HFI; OMIM #229600), which arises from a deficiency of aldolase B 
(EC 4.1.2.13). HFI prevalence can be as high as one in 20,000 live births, although it 
varies among ethnic populations (James et al., 1996; Santer et al., 2005; Gruchota et al., 
2006; Coffee et al., 2009).  
HFI first presents in infancy after weaning when fructose-containing foods are 
introduced into the diet. Symptoms after fructose ingestion vary, but infants often present 
clinically with failure to thrive, vomiting, diarrhea, jaundice, and/or other liver 
malignancies. Persistent intake of fructose can lead to hypoglycemia, non-alcoholic fatty 
liver disease (NAFLD), renal tubular failure, metabolic acidosis, seizures, coma, 
progressive cirrhosis of the liver, and eventually death (Morris, 1968; Baerlocher et al., 
1978; Laméire et al., 1978; Odièvre et al., 1978; Cox, 1993). This pathophysiology of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  A majority of this work was published in Oppelt, SA, EM Sennott, and DR Tolan, “Aldolase B 
knockout in mice phenocopies hereditary fructose intolerance in humans”. Molecular Genetics 
and Metabolism, vol 114 (445-450). 2015.  
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HFI has been attributed to a sequestration of intracellular phosphate in the un-utilized 
intermediate, fructose 1-phosphate (Fru 1-P) (Van den Berghe, 1978; Lanaspa et al., 
2012a), although the complete biochemical underpinnings leading to hepatosteatosis and 
other HFI symptoms are not well understood. It is of note that the anatomical 
manifestations of HFI are similar to those in metabolic syndrome (MBS), such as the 
build up of fat and scar tissue in the liver damage as seen in NAFLD.  
This chapter presents the creation and characterization of a mouse model for HFI, 
by targeted KO of the Aldo2 gene. Aldo2-/- mice were weaned onto diets free of fructose, 
or with exposure to a 40% (w/v) fructose solution, and their response was compared to 
Aldo2+/+ WT litter mates. Their ability to serve as a model for HFI was assessed by 
measuring mortality, liver enzyme activities, and liver histology following exposure to 
fructose. The Aldo2-/- mice showed a failure to thrive phenotype and liver pathology 
consistent with symptoms seen in human HFI patients.  
 
3.1 Generation and Characterization of an Aldo2-/- Mouse  
3.1.1 Generation of an Aldo2-/- mouse 
Aldo2-/- mice were generated by implantation of embryonic stem (ES) cells purchased 
from the Knock Out Mouse Project (KOMP) Repository (www.komp.org) into 
blastocysts (see Section 2.1.3). The ORF from the middle of exon 2 to the middle of exon 
9 was eliminated in targeted ES cells (See Fig 3.1). All four breeding pairs between 
chimeric BF-10 males and albino c57BL/6NTac females yielded germ-line transmission 
of the black coat color in the F1 pups (n=40, 24 male and 16 female). Of these F1 mice, 
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20 were confirmed as heterozygous for the Aldobtm1(KOMP)Vlcg allele using a PCR-
mediated genotyping scheme shown in Figure 3.1.  
 
3.1.2 Genotype analysis protocol using Polymerase Chain Reaction (PCR) 
To genotype mice, tails were snipped at weaning and incubated in 200 µl extraction 
buffer (Viagen) as is described in Methods 2.2. The genomic DNA from these prepared 
tail samples was used for PCR mediated genotyping (see Fig 3.1). Wild type DNA 
controls were from pKO6 (Coffee, 2010). DNA controls for homozygous Aldo2-/- or 
heterozygous Aldo2-/- were from tail snips of mice confirmed biochemically by liver 
aldolase activity assays to be of that genotype; mouse DP2, and mouse 1601, 
respectively.  
Five breeding pairs of heterozygous F1 males and females were used create an F2 
generation. F2 pups were genotyped from DNA isolated from tail snips of 93 F2 pups 
using PCR-based genotyping (see Fig 3.1), and showed a 22:45:26 ratio of 
Aldo2+/+:Aldo2+/-:Aldo2-/-. Representative genotypes of the F0-chimeric males, two of the 
F1 progeny, and all three genotypes found among the F2 progeny are shown in Fig 3.1. 
There was no significant difference in the numbers of F2 male and female Aldo2-/- 
progeny, and all appeared healthy at weaning. These results are consistent with the 
genetics of HFI (Steinmann et al., 2001), showing that the Aldo2-/- allele is inheritable by 
Mendelian genetics, and not embryonic lethal or sex-biased.  
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Fig 3.1 PCR-genotype analysis of Aldo2-targeted mice  
A) Schematics of the Aldo2 locus in wild type (WT) and the KOMP-tm1 deletion of the knockout 
locus (KO). Primer names are shown next to arrows indicating where primers anneal to each 
allele, while the bar underneath indicates the length of the fragment produced by primers in a 
PCR reaction. Primer sequences are in Table 2.1. The upstream primer SU2 was the same for 
both wild type and KO allele, while the downstream primers were specific for each (TUR2 and 
TUR2V, wildtype; LacInRev, KO). SU2 with TUR2 or TUR2V primers would yield a fragment of 
1,006 base pairs from WT DNA, and SU2 with LacInRev primers would yield a fragment of 512 bp 
from the Aldobtm1(KOMP)Vlcg allele. B) Agarose gel of PCR reactions from tail snips of mice for 
genotyping. Presence of both bands confirms heterozygosity, while one band confirms 
homozygosity. Chimeric males used for breeding the F1 generation (lanes 1 – 4), F1 breeders 
(lanes 5 and 6), and F2 progeny (lanes 7 – 9) are shown here.  
 
 
!"#
$%#
&'()*+(,#-./*0#
1###2####3###4###5###6###7###8####9#
: 1
#;
+*
*<
(=
>#
:2#?+@>*=A#
!"#B1CCC#;?D#
$%#B5CC#;?D#
1000 bp!
2! 3! 4! 5! 6! 7! 8! 9!1!
1! 2! 9!loxP
!
lox
P! neo! polyA!lacZ!
500 bp!
A
B
chimeric males
!"#
$%#
&'()*+(,#-./*0#
1###2####3###4###5# #6###7###8####9#
: 1
#;
+*
*<
(=
>#
:2#?+@>*=A#
!"#B1CCC#;?D#
$%#B5CC#;?D#
1000 bp!
2! 3! 4! 5! 6! 7! 8! 9!1!
1! 2! 9!loxP
!
lox
P! neo! polyA!lacZ!
500 bp!
F1 
breeders
F2 
progeny
SU2
SU2
TUR2
LacZinRev
	  	  
55	  
3.2 Confirmation of Aldolase-B Deficiency  
3.2.1 Enzymatic activity of aldolase in livers of Aldo2-/- and wild-type mice 
Enzyme activity assays of liver lysates from all three genotypes of F2 progeny were 
performed to confirm that the KO allele resulted in loss of aldolase B activity. Aldolase B 
activity was distinguished from aldolase A activity by comparison of these activities 
towards both aldolase substrates, fructose 1,6-bisphosphate (Fru 1,6-P2) and fructose 1-
phosphate (Fru 1-P). Residual specific activity from aldolase A in erythrocytes is >20 
fold more active when Fru 1,6-P2 is used as a substrate, compared to Fru 1-P (Gitzelmann 
et al., 1989a). By comparison, aldolase B in liver has values for Fru 1,6-P2:Fru 1-P ratio 
of 1 - 2 (Raivio et al., 1967; Lerner et al., 1987). Therefore, as the aldolase B protein 
concentration in a tissue decreases, the value for ratio of these activities increases from 
about 1 to >10 in preference of Fru 1,6-P2. As shown in Table 3.1, the three genotypes 
were significantly different in their aldolase activities toward both substrates (ANOVA, 
p<0.001). Activity toward Fru 1-P was undetectable in the Aldo2-/- mice, and resulted in a 
change in the Fru 1,6-P2:Fru 1-P activity ratio from 1.7 in wild-type mice to over 10 in 
Aldo2-/- mice, indicating that any remaining aldolase activity in Aldo2-/- mice was due to 
aldolase A, and that the aldolase B gene had, in fact, been deleted. The activity of 
fructose 1,6-bisphophatase was included as a measure of general liver health, to ensure 
that the drop in aldolase activity of the Aldo2-/- mice was due to the absence of aldolase B 
activity, and not liver failure in these mice.  
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Table 3.1 Liver enzyme activities are significantly different between genotypesa 
 
Genotype 
Fru 1,6-P2 
activity 
Fru 1-P 
activity 
Ratio 
Fru 1,6-P2:Fru 1-P 
FBPase 
Wild Type 
(Aldo2+/+) 
12.8 ± 2.2 7.6 ± 1.3 1.7 ± 0.4 26.7 ± 2.2 
Heterozygous 
(Aldo2+/-) 
6.9 ± 0.9 3.3 ± 0.9 2.1 ± 0.6 21.8 ± 4.8 
Homozygous 
(Aldo2-/-) 
1.4 ± 0.6 ND 14   ± 7 18   ± 3.7 
	  
a Activities in U/µg protein. All errors are SEM for n>3 determinations done in triplicate. ND 
indicates that activity was below the reliably detection limits of assay. Livers were harvested and 
frozen (–80 °C) prior to sonication from mice fed a diet of regular chow with 40% fructose (w/v) 
drinking solution. All three genotypes were analyzed for significance for each enzyme activity by 
ANOVA.	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3.2.2 Comparison of aldolase activity from livers of Aldo2-/- mice to human HFI patients 
In order for Aldo2-/- mice to be a valid model for fructose metabolism by HFI patients, 
Aldo2-/- mice should match the same criteria used to diagnose HFI in humans. 
Importantly, a comparison of published values of liver-aldolase activities toward both Fru 
1,6-P2 and Fru 1-P from normal humans and the activities from Aldo2+/+ (WT) mice were 
similar. Likewise, a comparison between patients with HFI and Aldo2-/- mice showed no 
significant difference between species (Fig 3.2 A) (p > 0.5 comparing mice to humans). 
These findings are important in confirming that the aldolase isozyme expression and 
activity between species is similar. The standard criteria for diagnosis of HFI in humans 
is the increase in the ratio of the liver-aldolase activities towards Fru 1,6-P2 over Fru 1-P 
(Laméire et al., 1978; Odièvre et al., 1978). In the Aldo2-/- mice, the ratio of Fru 1,6-
P2:Fru 1-P activity (14 ± 7) compared to the ratio of activities in WT mice (1.7 ±0.4) was 
similar to that seen in human HFI patients compared to non-HFI patients (Fig 3.2 B).  
 
3.3 Characterization of Aldo2-/- Mouse Phenotype  
3.3.1 Aldo2-/- mice show stunted growth when exposed to low concentrations of fructose 
in diet 
HFI patients exposed to low levels of fructose in diets, especially during infancy, exhibit 
a failure to thrive. Children will catch up in size to their peers after HFI is formally 
diagnosed and fructose is removed from the diet (Baerlocher et al., 1978). Interestingly, 
the Aldo2-/- mice tended to be smaller at weaning compared to their WT or Aldo2+/- 
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littermates when breeding pairs were not fed a strictly fructose-free diet. This indicated 
that pups were exposed to a low level of fructose found in the breeding chow (<0.3% 
(w/w) PicoLab mouse chow #5058). The exposure to fructose from the breeding chow 
would be comparable to a dose of less than 0.2 g/kg body weight, which is about five 
times the recommended limit for HFI patients (40 mg/kg (Cornblath & Schwartz, 1991), 
but about 10-fold less than normal human consumption (Gaby, 2005). Similar to human 
patients, the Aldo2-/- mice reached the same size as their littermates within two weeks 
after weaning, if fed a strictly fructose-free diet (Fig 3.3 A). Aldo2-/- mice left on a low-
fructose diet, and who continued to be fed breeder’s chow post-weaning, show stunted 
growth from which they did not recover, and remained smaller in size than their WT 
littermates (Fig 3.3 B).  
 
3.3.2 Mortality of Aldo2-/- mice to high quantities of fructose exposure  
Human patients with HFI are considered asymptomatic until fructose is introduced into 
the diet, after which liver damage, and eventually liver failure, occurs (Long et al., 1997; 
Steinmann et al., 2001). To assess the response of Aldo2-/- mice after fructose exposure, 
mice of all three genotypes were challenged with fructose within 1-2 days post- weaning. 
Mice were fed either a diet of regular chow and 40% (w/v) fructose in water (ad libitum), 
or a diet with fructose-free chow (Bio-Serv, Flemington, NJ) and water, and checked 
daily for survival. Mice were weighed every two days as a measure of growth. The 
heterozygous and homozygous wild-type mice showed no difference in mortality 
regardless of the diet; all survived regardless of diet for the three-week testing period.  
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Fig 3.2 Aldolase activity of Aldo2-/- mice livers is similar to that seen in HFI patientsʼ livers  
Panel A) Human HFI and Aldo2-/- mice show similar levels of aldolase activity. Specific activities 
(U/g wet weight) measured from livers of wild type (black) and Aldo2-/- mice (white) were 
compared to previously published aldolase activity measured from livers of unaffected humans 
(homozygous; dark gray) and of HFI patients (light gray). WT and Aldo2-/- mice were fed a 
fructose-free diet. Human liver aldolase activities were from (Levin et al., 1968; Koster et al., 
1975; Steinmann & Gitzelmann, 1981). Asterisks denote significant differences (p< 0.05) in 
pairwise comparisons using student t-test. Panel B) The Fru-1,6-P2:Fru-1-P ratios of aldolase 
activities from mouse (black) or human (grey (Hers & Joassin, 1961; Levin et al., 1968; Schapira 
et al., 1974; Koster et al., 1975; Steinmann & Gitzelmann, 1981; Muller-Wiefel et al., 1983) liver 
tissue with either normal/WT (homozygous) genotype or HFI/Aldo2-/- genotype.  
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Fig 3.3 Fructose stunts growth of Aldo2-/- mice 
A) Either Aldo2-/- (white box) or Aldo2+/+ (black box) pups (n≥5) were exposed to low levels of 
fructose prior to weaning and weighed every two d for 24 d. B) Aldo2-/- (light grey box) or Aldo2+/+ 
(black box) mice (n≥5) were fed breederʼs chow post-weaning for ≥ 21 days, and then sacrificed. 
Weights were compared for significant differences using a studentʼs t-test; asterisks denote p < 
0.05 between genotypes. 
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However, all Aldo2-/- mice showed a severe mortality rate when exposed to fructose (Fig 
3.4 A), and expired within less than 48 h of fructose being introduced into the diet. This 
was in sharp contrast to Aldo2-/- mice on a fructose-free diet, where the mortality rate was 
indistinguishable from mice of other genotypes (Fig 3.4 B), with all Aldo2-/- mice on a 
fructose-free diet surviving.  
The response to fructose of recently weaned Aldo2-/- mice was then compared to 
the response of adult Aldo2-/- mice. Two adult female Aldo2-/- mice that were fed a 
fructose-free diet for three weeks were switched to normal chow with 40% (w/v) drinking 
solution, mice were checked for survival every day, and weighed every two days. One 
adult Aldo2-/- mouse expired after 48 h, similar to the recently weaned mice. The other  
Aldo2-/- mouse, however, was better able to tolerate the fructose load. It lost nearly half of 
its body weight over the course of 7 days, during which it was weighed every day. It was 
then switched back to a fructose-free diet, and regained weight back to its former size 
within 5 days of removal of dietary fructose (Fig 3.5). It remained indistinguishable from 
WT littermates for another 10 days after fructose removal, and was then sacrificed. The 
liver was dissected out for subsequent histological staining with H&E (see Section 3.3.6). 
This indicates that, while still severe, the effects of fructose on adult Aldo2-/- mice is more 
variable, with a better chance of survival, than in young mice. 
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Fig 3.4 Exposure to fructose causes mortality in Aldo2-/- mice 
Exposure to dietary fructose affects morbidity of Aldo2-/- mice. Mice of all three genotypes noted 
in key in the keys (n>=3) were fed either regular chow and 40% fructose solution (A), or fructose-
free chow and water (B) and observed for morbidity every day for 21 d, or until natural death.  
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3.3.3 Aldo2-/- mice have hepatomegaly and hepatosteatosis 
Characterization of the changes and/or damage to the livers of Aldo2-/- mice after 
concentrated fructose exposure was examined histologically. Mice with a WT or an 
Aldo2-/- genotype were fed either a fructose-free diet or a diet supplemented with 40% 
fructose in the water for three weeks, or until expiration. Aldo2-/- mice that expired due to 
fructose ingestion showed abnormal gross anatomy of the liver (Fig 3.6). Aldo2-/- mice 
exposed to fructose always showed hepatomegaly and hepatosteatosis. In addition, even 
Aldo2-/- mice only exposed to the low fructose breeder’s chow until weaning, and then a 
fructose-free chow, also showed enlarged livers with increased fat content, though to a 
lesser extent and with more variability between individual mice.  
 
3.3.4 Aldo2-/- mice have altered hepatic cell morphology and increased inflammation of 
the liver 
Due to the differences in gross liver morphology between WT and Aldo2-/- mice, 
histological examinations of livers were made. WT and Aldo2-/- mice were sacrificed, 
livers were harvested immediately on ice from sacrificed mice, or within 12 h 
postmortem from Aldo2-/- mice that expired overnight. In both cases, after dissection 
livers were then frozen (–80 °C) for further staining. Frozen livers were either later fixed 
with paraformaldehyde (PFA) or prepared for staining with Oil Red O. PFA-fixed livers 
were subsequently embedded in paraffin and subjected to hematoxylin and eosin (H&E) 
staining (Fig 3.7). H&E staining revealed an increase in inflammatory cells and an  
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Fig 3.5 Adult Aldo2-/- mouse weight over the course of being exposed to, and recovering 
from, a high fructose load 
An adult Aldo2-/- mouse raised on a fructose-free diet for three weeks post-weaning was exposed 
to fructose at day 21. The Aldo2-/- mouse had ad libitum access to normal chow and a 40% (w/v) 
fructose drinking solution for seven days before being returned to a fructose-free chow and 
normal drinking water. Arrows indicate the switch in diets, first by introducing fructose, and 
second, by removing it. Days when mouse was exposed to fructose are marked with red 
diamonds. Weight was recorded every two days, and survival was monitored daily.  
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Fig 3.6 Aldo2-/- mice have enlarged livers with increased fat content and altered organ 
texture 
Resection of aldo2+/+ (left) and aldo2-/- (right). Livers from Aldo-/- mice after expiration due the 
fructose ingestion were enlarged, and were clearly discolored due to an increased fat content, 
with a firmer texture than WT counterparts.  	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increase in fibrotic stress fibers in livers from Aldo2-/- mice compared to WT mice, after 
exposure to 40% (w/v) drinking solution. Interestingly, both genotypes that were given 
the 40% (w/v) fructose drinking solution showed more vacuoles and altered nuclear 
staining (Fig 3.7, left panels). However, it is important to remember that these alterations 
occurred during 21 d of fructose exposure in the WT mice, whereas the changes seen in 
the Aldo2-/- mice occurred within the first day of exposure. 
 
3.3.5 Aldo2-/- mice livers have increased lipid content  
One hallmark of HFI is the rapid appearance of hepatic steatosis, characteristic of 
NAFLD (Odièvre et al., 1978; Stormon et al., 2003). Detection of fat droplets in Aldo2-/- 
and WT mice livers was done by staining of frozen livers with Oil Red O. A high 
fructose load caused an increase in lipid staining, compared to a fructose-free diet, in both 
genotypes (Fig 3.8, right panels). In Aldo2-/- mouse livers from mice exposed to a high 
fructose load, there was also significant tissue damage, shown by tearing of the tissue 
(white spaces in liver section) (Fig 3.8, bottom right). Furthermore, there was also an 
increase in lipid deposits in livers from Aldo2-/- mice compared to that from WT mice, 
even with little or no fructose in the diet for 21 d (Fig 3.8, left panels). The current cause 
of this increased fat, absent of a fructose insult, is currently unknown.  
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Fig 3.7 Histology of WT and Aldo2-/- mice liver sections with and without exposure to 
fructose  
Livers from Aldo2+/+ (WT) or Aldo2-/- (KO) mice on fructose-free (0% fructose) diet or fructose 
drinking solution (40% (w/v) fructose) were dissected after 21 d exposure, or at time of natural 
death (1-2 d, KO mice), and stained with H&E as described in Section 2.3.4. Arrow points to 
macrophage, arrowheads point to forming stress fibers as a part of fibrosis. All micrographs were 
taken at 40X magnification and scale bar is equal to 50 µm. 
	  	  
68	  
 
 
 
 
 
 
Fig 3.8 Aldo2-/- mice livers have more oil deposits and incur more damage after fructose 
exposure than Aldo2+/+ mice 
Livers from Aldo2+/+ (WT) or Aldo2-/- (KO) mice on fructose-free (0% fructose) diet or fructose 
drinking solution (40% (w/v) fructose) were dissected after 21 d exposure, or at time of natural 
death (1-2 days, KO mice), and stained with Oil Red O as described in Section 2.3.5. White 
spaces in the bottom right panel are from tears in liver tissue of KO mice, due to severe tissue 
damage. All micrographs were taken at 40X magnification and scale bar is equal to 50 µm. 
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3.3.6 Fructose-exposed Aldo2-/- mice will recover in body weight and liver health if 
fructose is removed from the diet  
Prior to diagnosis, many children with HFI suffer failure to thrive due to liver damage 
caused by the ingestion of fructose after weaning. However, after diagnosis and dietary 
fructose removal, these children can fully recovery. Histology of livers from young (11 
week old) Aldo2-/- mice exposed to fructose, then treated by removal of fructose from the 
diet, was compared to published liver histology from young HFI patients who had similar 
treatment for HFI, with removal of dietary fructose for three weeks prior to patient biopsy 
(Fig 3.9) (Odièvre et al., 1978). Both the human and mouse livers had large oil vacuoles 
remaining (stained red in the mouse liver, and seen as white circular spaces in the human 
liver). The similarity between these two livers is striking, and is a further indication that 
this Aldo2-/- mouse is an appropriate model for HFI.  
 
3.4 Summary 
Many of the major characteristics of HFI pathophysiology were exhibited by the Aldo2-/- 
mice. Infants with undiagnosed HFI have an acute intolerance to fructose ingestion, 
which leads to coma or death after large or persistent fructose exposure (Baerlocher et al., 
1978; Cornblath & Schwartz, 1991). Older children exposed to chronic, low amounts of 
fructose show a failure to thrive with hepatic steatosis and fibrosis (Baerlocher et al., 
1978). The Aldo2-/- mice replicated all of these conditions. However, under different 
levels of fructose exposure, it is not known whether these mice may or may not  
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Fig 3.9 Aldo2-/- mice show similar liver morphology after complete fructose removal from 
diet as do children diagnosed with HFI 
A and C, human liver sections adapted from Ryan et al., 2002 showing a normal human liver, and 
Odièvre et al., 1978 of a child with HFI who was exposed to fructose prior to diagnosis of HFI and 
treated by removal of fructose from the diet for three weeks prior to analysis. B, Oil Red O 
staining of a liver section from a WT adult mouse on a normal chow diet. C, Oil Red O staining of 
a liver section from an eight-week old Aldo2-/- mice (n=1), raised on fructose-free chow, were then 
exposed to fructose as a 40% solution ad libitum for 7 days, after which fructose was removed 
and the mouse was allowed to recover for 10 days before sacrifice and liver dissections. Red O 
staining analyzed liver sections and micrographs were taken at 40X magnification.  
1120 Ryan et al 
Figure 4. US imaging and liver biopsy evaluation of 
hepatic steatosis. (A) Abdominal US examination inter- 
preted as &&e  fatty  infiltration. (B) Corresponding  per- 
cutaneous  liver  biopsy  in  the  same  patient  showing no 
evidence of fatty  change. 
nificant discordance rate when commenting on the 
efficacy of imaging donor livers for the presence of 
steatosis. They found MRI and CT failed to detect 
biopsy-proven steatosis in 30% and 24% of cases, 
respectively. The significance  of 10%  to  30%  hepatic 
steatosis is suggested by modeling  studies  on  our  group 
of 53 donor  candidates  with  no  hepatic fat whose livers 
ultimately were used for donation. The presence of 
20% fat in  these livers would have decreased the 
GRBW in 22% of these candidates to a level below 
0.8%.Unlike Rinella,26 who s ate that steatosis was 
always present on biopsy when imaging  studies  identi- 
fied fat, we did  not find  this  to be the case. Imaging 
reported  steatosis  (in  one case as diffuse steatosis) in two 
donors  with 0% fat on biopsy  (Fig. 4)  and  one  with 7% 
to 10% steatosis.  Four more  donor  candidates  with  no 
fat  on biopsy were diagnosed as having  mild  steatosis. In 
addition,  a  normal biopsy with  no  evidence  of fibrosis 
was obtained  in  one  donor  candidate  thought  to have 
possible cirrhosis on scan. Miller25 also found  that  in 
several  cases (7 patients)  imaging  identified  steatosis  in 
their  prospective  donors  when  there was actually none 
on biopsy. 
Noninvasive  modalities previously have been 
assessed to  determine  their  ability  to  quantitate  in vivo 
hepatic  fat  content.  However few published series  exist 
specifically evaluating  the livers of  potential  living 
donors.  Although  our  protocol  did  not  employ  MRI 
scanning,  our  35%  error ate was not significantly  dif- 
ferent  from  the  30%  error  rate  reported by Rinella26 
with MRI imaging. Miller describes 7 false positives 
with scans, either  MRI  or CT, in  a large  series of 109 
donors,*5 but  not all candidates  had liver biopsies,  lim- 
iting  the usefulness of  the  data  to  determine  the precise 
correlation  rate  between scan and biopsy. MRI is tradi- 
tionally  regarded as more  accurate  in  detecting  smaller 
quantities  of at.35 However, when  compared  to US it is 
2 to 3 times more expensive and requires  longer  exam- 
ination time creating significant scheduling difficul- 
ties.31 Prospective  studies  further  evaluating and  com- 
paring  the  accuracy  of specific imaging  techniques  in 
living  donor  populations are needed so that these issues 
can be addressed. In  our  particular  study,  which was 
retrospective, Hounsfield's units were not specifically 
reported  on CT scans and  whether  this  would  add fur- 
ther accuracy could be an additional  avenue  of  investi- 
gation. 
In  addition  to steatosis we detected  a  variety  of  other 
findings  in 38%  of prospective  donors. In  this  group, 
nonspecific  triaditis was the  most  common  condition, 
affecting  half (19 of 38) of the  donor  candidates.  In 
addition, other biopsies exhibited mild fibrosis, both 
portal  and  sinusoidal;  mildly  increased  hepatocellular 
iron;  sinusoidal  dilatation; and poorly formed  granulo- 
mas. None  of these  entities were deemed severe enough 
to  deny  the  donation. However, the histology  in  three 
additional  patients was regarded as sufficiently  patho- 
logic  to  negate liver donation.  Two suffered  from 
chronic  hepatitis  with fibrosis, one  with  incipient 
bridging. Both had a BM1 of 26 and normal liver 
enzyme levels. The  third  patient  with  a BM1 of 20 and 
normal liver e zymes had an ill-defined vascular lesion, 
bile duct  proliferati n,  and fibrosis. In those  programs 
in  which  donor  candidates are not  routinely biopsied, 
or biopsied only if their BM1 is over 28, these three 
donors  would have gone on  to surgery. The  outcome 
for both  donor  and recipient cannot be known  with 
certainty,  but  deeming  donor safety to be of paramount 
importance, we  believe the  potentially  increased risk to 
these  donors was not  justified.  Reports  of  pathologies 
A B
C D
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Table 3.2 Pathologies in HFI patients and the Aldo2-/- mouse model 
  
HFI 
patients 
Aldo2 -/- 
mouse 
Acute hypoglycemia with fructose exposure yesa,b yesh 
 mortality upon fructose over-exposure yes c yesi 
 build up of Fru 1-P in livers with fructose exposure yesa,b ND 
 hypermagnesiamia yesd yesh 
 hypophosphatemia yesd yesh 
 hyperfructosemia yesd ND 
 hyperfructosuria yesd ND 
 hypothermia with fructose exposure ND yesh 
 hyperuricouria ND yesh 
Chronic failure to thrive yesc yesi 
 recovery of vigor with treatment* yesc yesi 
 NAFLD with fructose exposure yese,f yesi 
 persistent fatty liver with treatment yese,f yesi 
 inflammation and fibrosis with fructose exposure yese,f yesi 
 ectopic expression of alternative aldolase isozymes yesg ND 
 
ND = not determined 
aHers & Joassin, 1961  
bFroesch et al., 1959  
cCox, 1993  
dLevin et al., 1968  
eBaerlocher et al., 1978  
fOdièvre et al., 1978  
gSchapira et al., 1974  
hpersonal communication, D.R. Tolan and M. Lanaspa 
iOppelt et al., 2015  
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experience other attributes of HFI, such as prolonged hypoglycemia, renal tubular 
acidosis, hypophosphatemia, or lactic acidosis (Steinmann et al., 2001) (Table 3.2).  
Moreover, these experiments provide information about the effects of high 
fructose ingestion on WT mice. While WT mice did not have the same morbidity after 
fructose exposure, there were noticeable changes liver cytostructure and fat buildup  
 (see Fig 3.8). More investigation of biomarkers of fructose metabolism and its pathology 
among Aldo2-/- mice, WT mice, and comparisons to humans is now possible. 
Given the clear mimicking of HFI, the Aldo2-/- mice provide a valuable animal 
model to test potential treatments for HFI. Interestingly, some of the symptoms seen in 
HFI patients, as well as these mice after small amounts of fructose exposure, are similar 
to those seen in patients developing MBS due to prolonged fructose ingestion (Lim et al., 
2010; Sun et al., 2011; Lustig et al., 2012). The parallel hepatosteatosis in HFI and 
NAFLD connect these acute and chronic pathologies, respectively.  
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CHAPTER 4: Specific regions of the brain can participate in extra-hepatic fructose 
metabolism in the body 
For a tissue to participate in fructose metabolism, dietary fructose must be transported 
from the blood stream into the cells of those candidate tissues. GLUTs 2, 5, 7, 8, 9, and 
11 are all known fructose transporters, though there is some ambiguity on the ability of 
GLUT8 to translocate to the plasma membrane in all tissues (see Section 1.2.1). Once 
inside the cell, fructose will be phosphorylated by either the fructose-specific KHK to Fru 
1-P, or will compete with glucose for phosphorylation by HK to Fru 6-P. The 
phosphorylated hexose will be cleaved by aldolase to DHAP and glyceraldehyde (if 
phosphorylated by KHK) or glyceraldehyde-3-phosphate (G3P) (if phosphorylated by 
HK). In order for glyceraldehyde to join the pool of glycolytic metabolites, it needs to be 
phosphorylated by triose kinase (DAK). The KHK-mediated Fru-1-P pathway and HK-
mediated Fru-6-P pathway are compared in Fig 1.1.  
 In this chapter, the capacity of the brain to metabolize fructose was first 
predicted using a bioinformatics approach to predict tissues that express genes in the 
fructose-specific metabolic pathway. These genes included the fructose transporting 
Gluts (Glut2, Glut5, Glut6, Glut7, Glut8, Glut9, and Glut11), Khk, AldoB, AldoC, and 
Dak. Glut6 was also included in this analysis, because it shares a conserved residue 
shown to be important for fructose transport in other fructose transporters, and its own 
transport parameters are unknown (see Section 1.2.1). Tissues in human outside of the 
liver and kidney predicted to be capable of fructose metabolism were identified by 
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bioinformatic analysis using the VNB (Funari et al., 2010). This analysis revealed 
significant expression of genes necessary for fructose metabolism in the brain. 
Subsequent in situ hybridization of brain slices, along with measurements of specific 
activity of the enzymes KHK and aldolase, confirmed the expression of these proteins. 
Finally, measurement of hexose oxidation rates of dissected brain tissue was used to 
investigate the rate of fructose metabolism and the contribution of KHK versus HK to 
this metabolism in the brain. It is clear that several regions of the brain, including the 
cerebellum, hippocampus, cerebral cortex, and olfactory bulb, are capable of fructose 
metabolism. Additionally, this fructose metabolism is enhanced in brains after exposure 
to high-fructose in the diet.  
 
4.1 Identifying Organs Outside of the Liver and Kidneys that Could Participate in 
Fructose Metabolism 
4.1.1 VNB predicts the brain as a site for fructose metabolism 
Prediction of tissues other than the liver and kidneys that express genes required for 
fructose metabolism via the Fru-1-P pathway was preformed using a bioinformatics 
approach aimed at physiomic assessment of gene expression. The VNB (Funari et al., 
2010) was used to compile qualitative and quantitative expression profiles of each gene. 
By entering the RefSeq sequences of each human cDNA (and its aligned paralogs) for the 
genes in the Fru-1-P pathway (known fructose transporters Glut2, Glut5, Glut7, Glut9, 
and Glut11, and possible fructose transporter Glut6; Khk, AldoB, and AldoC) into the 
VNB program, a list of tissues expressing this set of genes was compiled. The total 
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number of EST sequences in dbEST for each gene was tallied for each tissue. This 
generated a qualitative profile of gene expression per tissue. Tissues that had more than 
two hits for each gene in the Fru-1-P pathway were considered for further analysis (Table 
4.1). Because of annotation differences between studies, closely related samples that 
seemed to be from the same tissue type were grouped; for example, “cerebrum”, 
“cerebellum”, “nervous tissue”, and “brain” were all considered to be part of the 
“brain/nervous tissue”.  
A more stringent quantitative gene expression profile was generated by VNB, 
which tallied EST sequences from only those cDNA libraries in dbEST that have not 
been manipulated. In this quantitative profile, the level of expression of each gene was 
calculated as a percent of the total mRNA population in each tissue (Table 4.2). Tissues 
were considered to have expression of all genes in the Fru-1-P pathway and to be worthy 
of further investigation if they had quantitative level for each gene of >0.001% of total 
transcripts, with at least two hits in the qualitative profile were considered. The VNB 
correctly identified the liver and kidney as sites for expression of all genes necessary for 
this pathway (Table 4.2). Since KHK is the enzyme that determines whether a cell has a 
pathway specific for fructose metabolism, tissues are in the order of the percentage of 
Khk mRNA compared to all mRNA in the cell. As expected, liver was among the top four 
tissues in terms of expression levels for each of these genes, or set of genes (as in the case 
of the Aldos and Gluts). Kidney was among the top 19 tissues for these same genes. 
Notably, spleen/lymphoreticular tissue and brain/nervous tissue were in the top four  
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Table 4.1 Qualitative lists of tissues predicted to express genes in the Fru-1-P 
pathwaya 
 
Top tissues Khk Aldosb  Dak Glutsc 
Liver 37 472 31 50 
Kidney 20 95 22 115 
Lymphoreticular 
Tissuesd 12 178 77 81 
Brain and 
Nervous Tissuee 55 2256 84 156 
Testis 2 52 51 90 
Placenta 2 200 18 28 
Uterus 2 91 10 11 
 
aTissues having at least two “hits” for all genes in the Fru-1-P specific pathway  
were included 
bAldos included the sum of both AldoB and AldoC predicted to be expressed in 
tissue 
cGluts included the sum of all fructose-transporting Gluts predicted to be expressed 
in tissue, including Gluts 2, 5, 6, 7, and 9 
dLymphoreticular tissues include summed hits from the spleen, lymphoreticular,  
and lymph node.  
eBrain and nervous tissues include summed hits from brain, cerebellum, cerebrum, 
and nervous tissue.  
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Table 4.2 Tissues and their quantitative prediction of expression for genes in  
Fru-1-P pathwaya 
 
 Khk Aldosb Dak Glutsc 
Tissued rank % rank % rank % rank % 
Liver 1 0.015 2 0.277 2 0.029 4 0.023 
Kidney 2 0.008 19 0.049 18 0.003 13 0.010 
Lymphoreticular Tissuesd 3 0.006 16 0.077 1 0.030 3 0.029 
Brain and Nervous Tissuee 4 0.005 6 0.224 10 0.007 15 0.007 
Testis 5 0.001 20 0.049 16 0.004 26 0.004 
Placenta 6 0.001 15 0.087 9 0.007 9 0.013 
Uterus 7 0.001 18 0.061 14 0.006 16 0.007 
 
a Quantitative expression in human tissues was calculated by dividing the number of hits for a 
particular gene by the total number of ESTs for all genes in that tissue. This gives a reliable 
estimate of percent transcripts of a gene compared to total mRNA (Funari et al., 2000).  
bAldos included the sum of both AldoB and AldoC  
cGluts included the sum of all fructose-transporting predicted, including Gluts 2, 5, 6, 7, and 9 
dLymphoreticular tissues include summed hits from the spleen, lymphoreticular, and lymph node.  
eBrain and nervous tissues include summed hits from brain, cerebellum, cerebrum, and nervous 
tissue  	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tissues predicted to have high expression of Khk, with expression levels for the other 
genes (Aldos and Gluts) higher than or comparable to kidney. By mass, the brain is the 
largest of these organs, and is the focus of these experiments. The percentage of Khk 
expression in the brain/nervous tissue (0.005) was one-third of the liver (0.015) and 
nearly that of the kidney (0.006). Among the fructose transporters, Glut5 was 
quantitatively predicted to be in the brain, while Gluts 2, 7, and 11 were not. Overall, 
there was generally little to no expression of Glut7 in most tissues, whereas Glut9 
showed low expression levels in the brain and other tissues (Table 4.3).  
 
4.1.2 In situ hybridization identifies certain brain regions that express genes specific to 
the Fru 1-P pathway 
Expression of genes necessary for fructose metabolism in the brain/nervous tissue (Table 
4.1) was verified by in situ hybridization. Both sense (non-complementary) and antisense 
(complementary) DIG-labeled RNA probes were generated for Glut5, Glut6, Glut9, Khk, 
AldoC, and Dak (see Section 2.2.2). Each probe was used in succession on adjacent 14 
µm coronal slices of brains from adult male BL6 mice. Sense probes hybridized to tissue 
at background levels for all of the genes tested (Fig. 4.1), indicating that probes did not 
non-specifically bind.  
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Table 4.3 Qualitative percent expression of different fructose-transporting GLUTs 
in tissuesa 
 
Tissue GLUT2 % 
GLUT5 
% 
GLUT6 
% 
GLUT7 
% 
GLUT9 
% 
GLUT11 
% 
Liver 0.02 0.0015 nd nd nd nd 
Kidney 0.0047 0.0027 0.0054 nd nd nd 
Lymphoreticular Tissueb 0.0097 0.0179 0.0097 nd nd nd 
Brain and Nervous 
Tissuec nd 0.0019 0.0055 nd nd
d nd 
Testis nd 0.0023 nd nd nd nd 
Placenta 0.0029 0.002 0.0071 nd 0.002 nd 
Uterus nd nd nd nd 0.0022 nd 
 
aQuantitative expression in human tissues was calculated by dividing the number of hits for a 
particular gene by the total number of ESTs for all genes in that tissue. This gives a reliable 
estimate of percent transcripts of a gene compared to total mRNA (Funari et al., 2000). 
bLymphoreticular tissues include summed hits from the spleen, lymphoreticular, and lymph node.  
cBrain and nervous tissues include summed hits from brain, cerebellum, cerebrum, and nervous 
tissue.  
dBrain and Nervous Tissue had 3 hits from the qualitative profile, but not enough hits from the 
unmanipulated EST databases to give a quantitative percent expression estimate 
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Fig. 4.1 Sense probes hybridize at background levels  
Coronal slices (14 µm) of adult mouse brain were probed with DIG-conjugated sense mRNA of 
the same sequence as the genes for ketohexokinase (Khk), aldolase C (AldoC), triosekinase 
(Dak), GLUT5 (Glut5), GLUT6 (Glut6), and GLUT9 (Glut9). Sections are from either the 
cerebellum or cortex, both regions where anti-sense probes show specific binding. Expression 
was visualized by color development from horseradish peroxidase-conjugated anti-DIG antibody. 
Slices for Khk probes were unavailable for photographing. Images were taken at 20X 
magnification. Scale bar represents 100 µm.  	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Using the antisense probes, it was clear that certain regions of the brain expressed 
all of the genes in the Fru-1-P pathway, but that expression was not ubiquitous through-
out the brain. The cerebellum, hippocampus, cortex, and olfactory bulb (see Section  
2.4.2, Fig 2.1) were identified as having higher proportions of Fru-1-P positive 
expressing cells than other brain regions. Sections of the cerebellum (Fig. 4.2) showed 
strong Khk expression in the Purkinje cell layer (PCL), while the molecular cell layer 
(MCL) and granular cell layer (GCL) have little to no expression (Fig. 4.2, top left). 
Interestingly, Khk expression is not ubiquitously expressed in the PCL, but instead is 
expressed in an alternating pattern of Khk-positive and Khk-negative Purkinje cells. 
While a number of proteins are differentially expressed in the PCL, KHK has not 
previously been reported to show this pattern. Expression of AldoC in adjacent slices 
showed the same pattern as Khk in the PCL (Fig. 4.2, top middle), while missing from the 
MCL and GCL, as is expected for aldolase C/zebrin II (Leclerc et al., 1992; Ahn et al., 
1994; Hawkes & Herrup, 1995; Abbott et al., 1996; Sarna et al.; Chung et al., 2008). 
Lastly, probes for Glut5, Glut6, and Glut9 detected expression in the PCL, also 
alternating between Gluts 5, 6, or 9-positive and Gluts 5, 6, or 9 negative Purkinje cells 
(Fig 4.2. bottom panels). It appears that all cells in the PCL are positive for Dak 
expression, in contrast to the other mRNAs for proteins that are specific for fructose 
metabolism. 
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Fig 4.2 Enzymes in the Fru 1-P pathway are expressed in an alternating pattern in the 
Purkinje cell layer of the cerebellum  
Coronal slices (14 µm) of adult mouse brain were probed with DIG-conjugated antisense mRNA 
complementary to the genes for ketohexokinase (Khk), aldolase C (AldoC), triosekinase (Dak), 
GLUT5 (Glut5), GLUT6 (Glut6), and GLUT9 (Glut9). Expression was visualized by color 
development from horseradish peroxidase-conjugated anti-DIG antibody. Scale bar represents 50 
µm. The cell layers are labeled in the upper left micrograph; PCL, Purkinje cell layer; MCL, 
molecular cell layer; GCL, granule cell layer. Arrow notes positive expression and arrowheads 
indicate negative expression. Cell layers were identified based on morphological features of the 
cerebellum.  	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Another brain region that showed expression of the Fru-1-P pathway genes was the 
hippocampus (Fig. 4.3). In all cell bodies in the hippocampal formation, there is strong 
expression of Khk. In addition, expression of AldoC and Dak was clearly apparent in 
these same regions of the hippocampus. Among the fructose transporters, it appears that 
Glut5 was not expressed in the hippocampus, while Gluts 6 and 9 were.  
In slices of the cerebral cortex, at least some cells in all layers were expressing 
Khk, AldoC, Glut5, and Glut9 (Fig 4.4). The expression of genes in the Fru-1-P pathway 
is not ubiquitous to all cells in the cortex, and it is ambiguous from the in situ data alone 
which types of neurons and/or glial cells were expressing these genes.  
Lastly, the in situ hybridization indicated strong expression of the genes in the Fru 
1-P pathway in the olfactory bulb (Fig. 4.5). Again, not all cells in this brain region 
expressed genes in the Fru-1-P pathway, but a select set of cells due. Cells were 
identified based on morphological characteristics, and neurons in the granule cell layer 
(GCL), the mitral cell layer (MCL), and the periglomerular cells in the glomerulus layer 
(GL) were positive for expression of Khk, and AldoC. These cells also expressed Glut5, 
Glut6, and Glut9, as seen in the in situ hybridization.  
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Fig 4.3 Cells in the hippocampal formation express genes necessary for fructose 
metabolism  
Antisense probes for the genes listed in the legend for Fig. 4.3 and noted in the bottom left of 
each panel were used for in situ hybridization of coronal slices (14 µm) of adult mouse brain. 
Scale bar represents 100 µm.  
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Fig. 4.4 Select cells in the cortex express genes necessary for fructose metabolism  
Antisense probes for the genes listed in the legend for Fig. 4.2 and noted in the bottom left of 
each panel were used for in situ hybridization of coronal slices (14 µm) of adult mouse brain. 
Scale bar represents 100 µm.  
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Fig. 4.5 Enzymes in the Fru 1-P pathway are expressed in certain layers of the olfactory 
bulb  
Antisense probes for the genes listed in the legend for Fig. 4.2 and noted in the bottom left of 
each panel were used for in situ hybridization of coronal slices (14 µm) of adult mouse brain. 
Scale bar represents 50 µm. The glomerulus layer (GL), mitral cell layer (MCL), and granular cell 
layer (GCL) are labeled in each panel. Cell layers were identified by morphological features.  
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4.2 Regions of the Brain Positive for Gene Expression of the Fru 1-P Pathway Genes 
Express Functional Proteins  
4.2.1 Western Blots show expression of GLUTs 5, 6, and 9 in Fru-1-P positive regions of 
the brain 
The regions of the brain with positive ISH labeling for the Glut5, Glut9, Khk and AldoC 
mRNAs were assessed for protein expression (GLUTs) and activity (KHK and aldolase). 
Brains were dissected, and the cerebellum, hippocampus, cerebral cortex, and olfactory 
bulb regions were combined to create a Fru 1-P-positive tissue sample. The activity of 
DAK was not measured in these samples, since it not specific to Fru-1-P metabolism. 
Protein samples were prepared by sonication, and clarified by centrifugation. The 
membrane portion (see Section 2.4.2) of these samples was analyzed by immuno-blotting 
for the fructose-transporting GLUTs 5 and 9. GLUT3, the main GLUT expressed in the 
brain (Gerhart et al., 1992), was used as a control. Western blots showed the combined 
Fru-1-P-positive regions of the brain express all three of GLUTs as predicted by in situ 
hybridization (Fig. 4.6). Bands for GLUTs 3, 5, and 9 all migrated near their predicted 
sizes (approximately 50-55 kDa, 45 kDa, and 55 KDa, respectively). There have been 
inconsistent reports of Glut6 expression in the brain (Doege et al., 2000). In Fig. 4.6, a 
single band was clearly detected using a GLUT6 antibody. This band migrates at 
approximately 40 kDa when the predicted protein size is 46 kDa. The procedures used 
here do not separate internal and plasma membrane protein fractions, so it is possible that 
GLUT6 is being modified somehow, and its presence on the plasma membrane is not  
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Fig. 4.6 GLUTs 5, 6, and 9 are not up-regulated in Fru-1-P brain regions after feeding with a 
high fructose diet 
Membrane proteins were extracted from pooled samples of Fru-1-P positive brain regions. 50 µg 
of protein were loaded into each lane, and PVDF membranes were blotted with primary 
antibodies to GLUTs 3, 5, 6, and 9. An antibody against the A1 subunit of Na+/K+ ATPase pump 
was used as a loading control. Samples from mice on normal chow diets are marked with “–” and 
samples from mice on high fructose diets are marked with “+”. Arrows indicate expected 
molecular weight and position of protein.  
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determined. For the hippocampus, where ISH showed little to no glut5 mRNA 
expression, GLUT9 is most likely responsible for fructose transport into these cells.  
 
4.2.2 Fru-1-P regions of the brain have functional KHK activity  
The amount of functional KHK and aldolase enzymes in the Fru-1-P-positive brain tissue 
was quantified by measuring enzyme activity (U/µg protein) in supernatant fractions of 
the sonicated Fru-1-P-positive brain samples (see Sections 2.4.1 and 2.4.4). Hexokinase 
was measured in these fractions as a baseline for enzyme activity in these brain regions 
(Table 4.4). When mice were fed standard chow, the specific activity of KHK in Fru-1-P 
positive brain regions (300 ± 15 U/µg) was nearly five times higher than in liver (65 ± 10 
U/µg) despite the use of different isozymes (KHK-A in brain, and KHK-C in liver) 
(Diggle et al., 2009). The specific activity of aldolase in Fru-1-P positive brain regions 
(757 ± 58 U/µg) was about 10-fold higher than in liver (71 ± 5 U/µg).  
 
4.2.3 Dissected brain slices from various regions of the brain oxidize fructose faster than 
liver slices  
To determine the physiological relevance of the proteins in the Fru-1-P pathway being 
expressed, the rate of fructose oxidation was measured in brain and liver tissue slices. 
Separate brain regions, identified by in situ hybridization (cerebellum, hippocampus, 
cortex, and olfactory bulb), and liver were dissected from adult male mice, left intact, and 
used for assay of fructose oxidation to carbon dioxide. By not homogenizing the tissue,  
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Table 4.4 Activities of enzymes in the Fru 1-P pathway  
in fructose-metabolizing brain samples 
 	   	   Specific	  Activity	  (U/µg)a	   	  
Tissue	   Enzyme	   Normal	  diet	   High	  Fructose	  Diet	   Fold	  Change	  Brain	   KHK	   300	  ±15	   900	  ±60*	   3	  ±0.25	  	   HK	   460	  ±40	   515	  ±38	   1.1	  ±0.13	  	   Aldolase	   757	  ±58	   909	  ±54	   1.2	  ±0.12	  Liver	   KHK	   68	  ±11	   139	  ±13*	   2	  ±0.38	  	   Aldolase	   71	  ±5	   173	  ±19*	   2.5	  ±0.31	  
 
a Specific activity of KHK, aldolase, and hexokinase were measured in the supernatant fractions of 
sonicated dissected brain (a combined sample of cerebellum, cerebral cortex, hippocampus, and 
olfactory bulb regions) or livers, from three week old mice with access to either normal chow and 
water, or chow and a 40% fructose w/v drinking solution since weaning. Enzyme activities are 
calculated as the mean of n ≥ 5 trials; asterisks represent p ≤ 0.002 in pairwise t tests between 
enzymes from brains of mice on different diets.	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the integrity of the cell membrane was maintained. This allowed for an indirect 
assessment of the transport of fructose into the cells by the candidate GLUTs, since tissue 
not transporting fructose into its cells will not be able to oxidize it. Table 4.5 shows the 
rate of carbon dioxide production by the tissue samples after the addition of radioactive 
fructose to the media containing the slices (see Section 2.4.8). As a control, the rate of 
glucose oxidation was measured for both tissues. The rate of oxidation of glucose and 
fructose by the liver was in the same range as reported previously (Funari et al., 2005). 
The glucose oxidation rates by the various brain regions (ranging from 9.5 ± 2 to 41 ± 10) 
were 2-20 fold higher than that of liver (2.8 ± 0.6), which is consistent with the higher 
glycolytic capacity of brain relative to the liver (Gaitonde & Richter, 1966). Importantly, 
all four Fru-1-P positive regions of the brain were able to oxidize fructose, which 
corroborated both the in situ hybridization and protein expression data. Moreover, the 
rates of fructose oxidation by these dissected brain regions (ranging from 1.9 ± 0.2 to 7.7 
± 3) were 15-150 fold greater than that of the liver (0.09 ± 0.02).  
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Table 4.5 Rates of oxidation of hexoses by different fructose-metabolizing regions of 
the brain compared to the liver 
 
 Glucose Fructose Ratio  
Tissue (µmol of CO2/mg wet weight•hour)a Glc/Fru 
Liver 2.8 ± 0.6 0.09 ± 0.02  
Cerebellum 9.5 ± 2.0 * 1.9   ± 0.2 ** 5 
Hippocampus 41    ± 10 * 6.2   ± 1 ** 6.6 
Olfactory Bulb 36     ± 5 * 7.7   ± 3 ** 4.7 
Cortex 24     ± 7 * 3.9   ± 0.4 ** 7.2 
 
 
aOxidation rates of glucose and fructose were determined and error expressed as 
standard error of the means for ≥3 trials. 
* denotes significant difference (p < 0.05) when sample is compared to liver.  
** denotes significant difference (p < 0.01) when sample is compared to liver.  
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4.2.4 KHK and HK both participate in fructose phosphorylation in the brain 
The determination that these particular regions of the brain (cerebellum, hippocampus, 
cortex, and olfactory bulb) are capable of fructose metabolism lead to the question, which 
of the two pathways, through Fru 1-P or Fru 6-P, are these regions utilizing? To answer 
that question, oxidation assays using radioactive fructose with dissected Fru-1-P positive 
brain tissues samples were performed with either 1 mM fructose alone, 1 mM fructose 
plus 2.5 mM glucose, 1 mM fructose plus 1 µM of a pyrimindinopyrimidine that inhibits 
KHK (100x excess of LD50) (Maryanoff et al., 2011), or 1 mM fructose plus both 2.5 
mM glucose and 1 µM the KHK inhibitor (Fig 4.7). The assays that either targeted HK 
(via outcompeting with glucose) or KHK (via small molecule inhibition) each show 
approximately 40% decline in fructose oxidation compared to assays using fructose 
alone. The assay containing both glucose and the KHK inhibitor showed that nearly 90% 
of fructose is metabolized by enzymes affected by these additions. Clearly, both KHK 
and HK play a major role in the metabolism of fructose and the Fru-1-P pathway is a 
major contributing pathway in these brain regions. 
 	  
 
 
	  	  
94	  
 
Fig 4.7 Inhibiting fructose phosphorylation by KHK or HK reduces total fructose oxidation  
Radioactive fructose (1 mM)(U-14C at 0.065-0.073 µCurie/mmol) was added to a mixture of 
dissected cerebellum, hippocampus, cortex, and olfactory bulb alone, in the presence of 2.5 mM 
cold glucose (to compete for HK phosphorylation), 1 µM of KHK inhibitor (pyrimindinopyrimidine), 
or both cold glucose and KHK inhibitor, for 1 h. The measured oxidation rates were the average 
of ≥3 assays. Asterisks denote statistical significance p < 0.05 between “Fru + Glc + KHK 
inhibitor” and “Fru only” measurements. 	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4.3 KHK Activity Increases in Brains of Fructose-Fed Mice 
4.3.1 KHK activity is increased in brains of fructose-fed mice 
In the liver, high amounts of dietary fructose induce an increase in KHK and aldolase B 
activity approximately two-fold (Koo et al., 2008). Similar increases in the brain would 
be indicate that dietary fructose can induce such changes in brain metabolism and 
confirm the importance of this pathway in those regions capable of this metabolism. 
KHK, HK, and aldolase activity were measured in Fru-1-P-metabolism positive brain 
samples and livers of mice exposed to high fructose diets for three weeks (see Chapter 2, 
section 2.1.2), and compared to littermates fed normal chow. As expected in liver, KHK 
and aldolase activity showed a significant increase in mice fed high-fructose diets 
compared to mice not exposed to fructose. This increase was 2-fold for KHK activity, 
and 2.5-fold for aldolase activity. Interestingly, KHK activity in the Fru-1-P positive 
brain samples of mice exposed to fructose also increased significantly over the activity in 
mice fed normal diets, by three fold (Table 4.4). Unlike the liver, aldolase activity in the 
Fru-1-P positive brain samples was not significantly different between diets. HK activity 
in the Fru-1-P positive brain did not differ in the brains of mice of different diets. This 
was expected since HK can participate in fructose metabolism, its expression or activity 
has not shown to be responsive to changes in dietary fructose. 	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4.3.2 Fructose-transporting GLUTs 5, 6, and 9 are not up-regulated in Fru-1-P positive 
brain regions after high fructose feeding 
While dietary fructose was able to increase KHK activity, there was no effect on the 
concentration of GLUTs 5, 6, or 9 after exposure to high fructose in our experiments. 
GLUT5 expression has previously been shown to be induced in response to increased 
dietary fructose in the liver, small intestine, and kidney (Burant & Saxena, 1994; Shu et 
al., 1998; Koo et al., 2008), and there have been only a few reports comparing 
measurements of GLUT5 in the brain after normal and high fructose diets (Shu et al., 
2006; Messier et al., 2007). In my work, there appears to be no increase in GLUT5 
expression in the Fru-1-P regions of the brain (Fig 4.8), indicating that the responsiveness 
of this transporter to its substrate may be tissue specific. There was also no increase seen 
in GLUTs 6 or 9.  
 
4.4 Summary 
Transcriptional profiling in human suggested the importance of the brain as a site for 
fructose metabolism by predicting that the expression levels of the enzymes in the Fru 1-
P pathway as being comparable to those in the liver. In situ hybridization of adult mouse 
brain slices showed that many cells across several brain regions express the genes 
necessary for fructose metabolism, although expression is not uniformly seen in all cells. 
Here, it can be seen that the cerebellum, the hippocampus, cortex, and olfactory bulb 
contain the high populations of cells expressing the genes in the Fru-1-P pathway. 
Together, these regions of the brain express the fructose-transporters GLUTs 5 and 9 
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transporters, and have specific activities of KHK nearly 5-fold higher than KHK activity 
found in liver. Oxidation assays of dissected brain regions from adult mice confirmed that 
these regions could actively metabolize fructose. Additionally, Warburg oxidation 
inhibiting either KHK activity, or hexokinase activity, towards fructose showed that both 
the Fru-1-P and the Fru-6-P mediated pathways contribute to total fructose oxidation by 
these brain regions. This is the first time that KHK activity in the mouse brain has been 
shown to be up-regulated with a high fructose diet. Interestingly, this rise in KHK activity 
was not accompanied by a rise in aldolase activity, as is seen with aldolase B in the liver. 
However, since KHK is an enzyme specific to fructose metabolism, this rise in KHK 
activity makes it clear that not only do some regions of the brain metabolize fructose, but 
that they also respond to changes in dietary concentrations of fructose. 
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CHAPTER 5: Discussion 
 
5.1 Understanding Fructose Metabolism Requires a Valid Animal Model  
Given the prevalence of animal models in the study of fructose metabolism and 
progression towards metabolic syndrome, it is critical to characterize and confirm that 
fructose metabolism and its consequences are similar in humans and animals used in 
studies of fructose metabolism, and if not, where they differ. It is also important to 
understand where in the body fructose is metabolized, and which are the predominant 
enzymes used in that metabolism, in order to predict metabolic flux via Fru-1-P or Fru-6-
P mediated pathways and their respective consequences. Here, the Aldo2-/- mouse is 
presented as a model for HFI and metabolic dysregulation after fructose consumption 
presenting pathology similar to that of humans with HFI. Finally, the brain is revealed as 
significant site for fructose metabolism, which may contribute significantly to the 
metabolic load of dietary fructose in addition to the liver or in times when the liver 
cannot metabolize fructose.  
 
5.1.1 The Aldo2-/- mouse as an animal model for metabolic dysregulation after fructose 
exposure 
HFI patients exhibit a build-up of fat in livers following fructose exposure, severe liver 
damage with high fructose loads, and a failure to thrive in HFI children exposed to low 
levels of persistent dietary fructose. HFI patients also present with a severe and persistent 
hypoglycemia (Froesch et al., 1959; Hers & Joassin, 1961), and this can be fatal 
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especially if the condition remains undiagnosed. The Aldo2-/- mouse developed here 
closely phenocopies human manifestations of HFI (see Chapter 3) (Oppelt et al., 2015). 
In addition, in unpublished data, the Aldo2-/- mice also present with severe and persistent 
hypoglycemia after a gavage containing fructose (Lanaspa, M. and Tolan, D.R., 
unpublished data). Given the clear mimicking of HFI, Aldo2-/- mice provide a valuable 
animal model to test potential treatments for HFI (see Section 3.4, Table 3.2).  
Continued investigation of the metabolic defects in these mice under a variety of 
conditions may extend the use of this animal model beyond the study of HFI to further 
our understanding of fructose metabolism in general. In HFI patients, most clinical 
attention is devoted to the liver, and other aspects of altered metabolism, or the 
contribution of other organs to dietary fructose metabolism, are not well studied. Nothing 
is currently known about the long-term consequences of HFI in human patients. Research 
into whether they have increased risks for liver cancer developing from NAFLD and/or 
fibrosis, or if they have problems with inflammation in the kidney or pancreas where 
AldoB is also expressed, would influence healthcare and treatment.    
Symptoms such as NAFLD are seen in both HFI patients with fructose exposure, 
and non-HFI humans with excessive fructose exposure (Ouyang et al., 2008; Vos & 
Lavine, 2013). Aldo2-/- mice exposed to low levels of fructose over time display 
hepatomegaly and fatty liver, one of the markers used to diagnose MBS. Do they show 
other symptoms of MBS, such as increased visceral fat, impaired insulin signaling, and/or 
kidney problems? These important questions will be answered through further study of 
these Aldo2-/- mice.  
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If so, the phosphorylation of fructose and the resulting Pi sink may be the first 
step in a cascade of different consequences all converging on MBS (Lanaspa et al., 
2012c; Khitan & Kim, 2013; Lanaspa et al., 2014; Mirtschink et al., 2015). Aldo2-/- mice 
develop negative symptoms after fructose ingestion much faster than current mouse 
models for MBS (days instead of months), and would be an effective tool for not only 
uncovering the biochemical pathways involved, but also for testing therapies that might 
prevent fructose phosphorylation or correct the metabolic imbalance that follows fructose 
over-consumption (see Section 5.3). 
Additionally, HFI patients present a current paradox in regards to 
gluconeogenesis (GNG). Like fructose metabolism, GNG is thought to happen mostly in 
the liver via aldolase B activity (Gitzelmann et al., 1989b). While AldoB deficiency in 
HFI patients clearly results in loss of the ability to metabolize fructose, patients do not 
lose the ability to regulate blood glucose levels and presumably still perform GNG. 
Aldo2-/- mice provide a clear model for investigating this enigma.  
 
5.1.2 Possible production of endogenous fructose via polyol pathway in HFI patients/ 
Aldo2-/- mice 
Interestingly, fat build up was seen in livers of Aldo2-/- mice never exposed to fructose 
(see Section 3.3.5, Fig 3.8), and removal of fructose from the diet in mice that were 
exposed to fructose (either 0.03% in breeding chow, or a 40% (w/v) fructose drinking 
solution) not does reduce lipid levels to those of WT counterparts (Fig 3.9). The current 
hypothesis is that fat accumulates as a result of fructose-induced de novo lipogenesis 
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(Tappy & Le, 2010), and presumably the source of fructose is from diet. However, 
fructose may be synthesized in vivo via the polyol pathway, especially in diets that are 
high in other sugars such as glucose (sometimes called dextrose, for D-glucose,) (Travis 
et al., 1971) (Fig 5.1). The sucrose-free chow #F6700 is 50% D-glucose (w/w) (see 
2.1.2). Dietary concentrations of glucose of 50% caloric intake can increase the flux of 
carbons into the polyol pathway in certain organs. The polyol pathway can be activated in 
the kidney by both high concentrations of glucose and/or salt in the blood, since high 
concentrations of glucose and salt can change the osmotic pressure in an organ. The 
polyol pathway converts glucose to sorbitol via aldose reductase to help regulate osmotic 
pressure and cell size (Srivastava et al., 2005). Sorbitol can then be converted to fructose 
via sorbitol dehydrogenase (Travis et al., 1971), introducing fructose into cells when 
diets are high in simple sugars, even if none of the dietary sugars are fructose. Over-
activation of the polyol pathway is known to cause diabetic complications in kidney and 
nerve cells (Srivastava et al., 2005; Lanaspa et al., 2013; Lanaspa et al., 2014). 
Quantification of gene expression and enzyme activity of aldose reductase and sorbitol 
dehydrogenase in liver and kidneys of Aldo2-/- mice could provide information on 
whether this pathway is activated and whether blocking this pathway can also reduce the 
amount of fat in livers of Aldo2-/- mice. If endogenously produced fructose is not the 
metabolic source of the fat in Aldo2-/- mouse livers, an as of yet unexplored pathway that 
is distinct from fructose metabolism might underlay some of the symptoms seen in  
Aldo2-/- mice and HFI patients.  
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Fig. 5.1 Conversion of glucose to fructose via the polyol pathway 
Schematic of reactions in the polyol pathway that lead excessive glucose in cells to be converted 
to fructose via aldolase reductase and sorbitol dehydrogenase.  
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5.1.3 Aldo2-/- mice as a model for investigating progression of NAFLD to fibrosis 
Little is known about the progression from NAFLD to fibrosis in HFI patients after 
fructose is removed from the diet. Here, it is clear that even in Aldo2-/- mice never 
exposed to dietary fructose, there is excess fat in livers. When fructose is introduced to 
the diet, there is an increase in macrophage recruitment and fibrosis (see Fig 3.7). Is this 
increase in inflammation due to the rate at which fat is building up when dietary fructose 
is introduced? Or, are there other mechanisms that are activated with fructose ingestion 
that cause inflammation and fibrosis on top of fatty liver? Aldo2-/- mice on a fructose-free 
diet have the potential to investigate the role fructose metabolism plays in the transition 
from NAFLD to liver fibrosis and metabolic syndrome.  
 
5.2 Fructose Metabolism in the Brain 
5.2.1 Validation of the brain as capable of fructose metabolism 
While it has been known for nearly 50 years that fructose can be metabolized by brain 
tissue from experiments conducted on cultured brain slices (Chain et al., 1969; Stein & 
Cohen, 1976; Wada et al., 1998; Izumi & Zorumski, 2009), the role of fructose 
metabolism by the brain in vivo has been controversial. Two factors have historically 
contributed to the hypothesis that fructose is not metabolized by the brain. First, fructose 
is unable to support full neural electrical activity in slice cultures from guinea pig brains 
at concentrations less than 20 mM (Bachelard et al., 1984). Second, the absence of 
aldolase B (Lebherz	  &	  Rutter,	  1969) and the reported absence of an active KHK (Hayward	  &	  Bonthron,	  1998), along with the apparently high Km of brain hexokinase 
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(Sols & Crane, 1954) would not allow for efficient competition with glucose for 
phosphorylation by HK.  
In the first instance, electrophysiological studies done on brain slices have looked 
at electrical activity across a region of the brain, and not at individual cells. It has been 
noted that fructose can support normal electrical activity of slices, though at 
concentrations of 20 mM (Bachelard et al., 1984); at lower concentrations of fructose, 
some activity is lost when measuring population spikes of stimulated neurons (Wada et 
al., 1998). However, measurements of ATP, phosphocreatine, and lactate production 
show that fructose maintains the same energy state as glucose, in spite of the loss of 
electrical activity. The in situ hybridization data presented here showed that there is 
clearly non-uniform expression of genes in the Fru-1-P pathway, especially in the cortex 
(see Section 4.1.2, Figs 4.2-4.5), which predicts that there are two populations of cells: 
those that can metabolize fructose during hypoglycemia, and those that cannot. The 
presence of two distinct cell populations would lead to inconsistent abilities within a 
given brain region to utilize fructose, with some cells in a region being able to maintain 
electrical activity when supplemented with fructose alone, while neighboring cells do not. 
Studies of this nature, which make recordings across a population of cells, and 
homogenize tissue to gather intracellular metabolites, do not show a distinction between 
these two populations. The reason for this cell-specific phenomenon, instead of a 
ubiquitously expressed pathway, requires further investigation into the differences 
between the two populations of fructose-metabolizing and non-fructose-metabolizing 
cells.  
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My data did not differentiate between neurons or glial cells as showing expression 
of the Fru-1-P pathway genes, except where morphology was obvious (as with the 
Purkinje cells of the cerebellum, and certain layers of the olfactory bulb). Another 
explanation for the inconsistent ability of fructose to maintain electrical activity in brain 
slices is because in some Fru-1-P positive regions, glial cells are responsible for fructose 
uptake and initial metabolism to lactate, which can be shuttled to neurons for further 
metabolism (Pellerin & Magistretti, 2004). Fructose may also be converted to glycogen in 
some astrocytes that store small amounts of glycogen (Dringen et al., 1993; Brown et al., 
2004), and broken down to glucose and/or lactate later. It may be that the processing of 
fructose is too slow in a glial-neuron shuttle to support electrical activity in neurons not 
able to metabolize fructose themselves.  
The second factor that contributes to the dogma that the brain does not utilize 
fructose involves the kinetic constants measured for brain-specific hexokinase (Sols & 
Crane, 1954). This argument assumes that fructose is metabolized in the brain via the 
Fru-6-P pathway, due to the lack of aldolase B in the brain (Lebherz & Rutter, 1969). The 
expression of KHK in the brain (Hayward & Bonthron, 1998) and a function for KHK-A 
in whole body fructose metabolism (Ishimoto et al., 2012) has only recently been 
confirmed. To date, KHK specific activity has not been measured in brain. Expression of 
KHK in brain has been shown in brain via qPCR and WB of whole brain samples (Diggle 
et al., 2009), where probes for the gene or protein give low signal. This is not surprising, 
given that the data presented here shows that most cells of the brain in fact do not express 
KHK; however certain brain regions do have populations of cells that express Fru-1-P 
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pathway genes. When these regions are examined individually, KHK activity and 
fructose oxidation is evident. This expanded knowledge on the enzymes available to 
metabolize fructose, contradicts the argument that fructose is not metabolized because of 
the kinetic parameters of HK-I, and updates it to include the Fru-1-P pathway as a 
possible pathway in at least some regions of the brain. 
   
5.2.2 Contribution of HK and KHK to fructose phosphorylation in brain 
My results show that both HK and KHK are each responsible for about 50% of fructose 
metabolism in brains from mice fed a normal chow diet (see Section 4.2.4, Fig 4.7). 
However, KHK activity is increased in brains of mice with mice exposed to high 
concentrations of dietary fructose. This is especially interesting, because not only does it 
show that the brain isoform of KHK is active, since KHK-A was originally predicted to 
not have activity (Asipu et al., 2003; Ishimoto et al., 2012) and KHK activity has not 
been directly measured in brain tissue previously, but that it is also inducible with high 
fructose diets. Whether this increase in KHK activity in the brains of mice fed high-
fructose diets influences the balance between Fru-1-P and Fru-6-P flux inside cells, or the 
metabolic fates following fructose ingestion, requires further investigation (see Section 
5.3.2).  
 
5.3 Tissue-Specific Flux of Fructose Metabolism 
Fructose is already known to be metabolized in the liver, kidney, and small intestine 
(Holdsworth & Dawson, 1964; Heinz et al., 1968; Heinz et al., 1975; Wolfe et al., 1975), 
	  	  
107	  
and here we show it can also be metabolized by the brain. In addition, skeletal muscle can 
uptake fructose via GLUT5, though skeletal muscle is thought to contribute minimally to 
overall whole-body fructose metabolism (Wick et al., 1953). Since negative 
consequences of fructose metabolism are thought to be due to the unregulated Fru-1-P 
pathway (Van den Berghe, 1978; Lanaspa et al., 2012a), understanding the enzymes 
involved in fructose metabolism by tissue and predicting flux through Fru 1-P or Fru 6-P 
is important.  
 
5.3.1 Predominant fructose-transporting GLUTs in different tissues  
Unlike blood glucose levels, which are tightly regulated in the body to stay around 5 mM, 
blood fructose levels depend almost entirely on diet, and because of this, vary wildly 
within a person as well as from person-to-person. Serum fructose concentrations have 
been measured to be anywhere from 1 mM to as high 5-10 mM following a meal (Mayes, 
1993; Burant & Saxena, 1994).  
In the liver, GLUT2 is thought to be the major fructose-transporting GLUT 
expressed. Recently, GLUT9 has also been found in the liver (Mueckler & Thorens, 
2013). GLUT2 has a Km value for fructose of 76-108 mM (Mueckler & Thorens, 2013), 
well below measured levels of circulating fructose. This Km value is also higher than any 
of the Km values for other fructose-transporting GLUTs expressed by other tissues that 
play a more minimal role in whole-body fructose metabolism (Table 5.1). Meanwhile, 
GLUT9 has a Km value for fructose of 0.42 mM (Manolescu et al., 2007). A liver-specific 
Glut9-/- mouse has been created, but so far, only changes in uric acid transport have been 
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investigated in this model (Preitner et al., 2013). Both GLUTs 2 and 9 have preferred 
substrates other than fructose (see Section 1.2.1, Table 1.2). Still, the liver is responsible 
for clearing 50-70% of dietary fructose on first pass (Holdsworth & Dawson, 1964; 
Wolfe et al., 1975), so the discrepancy between serum fructose levels and GLUT2’s 
affinity for fructose transport is of note when assessing which transporter is responsible 
for transporting the majority of fructose out of the blood stream. 
The small intestine expresses GLUT5 as well as GLUT2 (Mueckler & Thorens, 
2013). GLUT5’s affinity for transporting fructose is much lower than GLUT2, with a Km 
value of 0.65 mM (Table 5.1) (Manolescu et al., 2007). In the small intestine, GLUT5 is 
expressed on the apical membrane and transports dietary fructose into cells, where it can 
be transported out of intestine cells and into the blood stream by GLUT2. In this context, 
the low affinity of GLUT2 for fructose may serve as part of a mechanism for 
concentration sensing of fructose, since the equilibrium would lie towards GLUT5 
bringing fructose into the cell at lower concentrations than GLUT2 would push it out.  
In certain regions of the brain, data presented here show that both GLUTs 5 and 9 
are expressed, and it has been shown previously that the blood brain barrier expresses 
GLUT5 (Mantych et al., 1993). The Km values of these two GLUTs towards fructose are 
similar, 0.65 mM and 0.42 mM respectively (Table 5.1), and both are lower than the 
measured concentrations of serum fructose (1 mM up to 10 mM, and varying greatly 
depending on diet (Mayes, 1993; Burant & Saxena, 1994)). If these two proteins were 
expressed at equal levels on the plasma membrane, they might contribute roughly equally 
to fructose transport into cells. GLUT9’s preferred substrate is uric acid, and it also  
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Table 5.1 Affinities towards Fru of Major Fructose-Transporting GLUTs 
 
Major Fru-
Transporting 
GLUTs 
Km value 
toward 
Fru 
(mM) 
Tissue 
Distribution 
Effects of KnockOut in Mouse 
Models 
GLUT2 76-108a liver, kidney, pancreatic isleta 
impaired glucose transport and 
glucose sensing, hyperglycemia in 
fed state, severe hypoglycemia in 
fasted state, pancreatic islet 
damagec 
GLUT5 0.65b small intestine, kidney, braina 
impaired differentiation of WAT, 
fructose malabsorption, nutrient 
malabsorption and hypovolemic 
shock with high fructose dietsd,e 
GLUT9 0.42b liver, braina 
impaired uric acid transport, 
hyperuricosuria, urate nephropathy 
in both whole-body and liver-specific 
KO modelsf,g 
 
aMueckler & Thorens, 2013  
bManolescu et al., 2007  
cBerry et al., 2005  
dDu & Heaney, 2012  
eBarone et al., 2009  
fPreitner et al., 2009  
ePreitner et al., 2013  
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transports glucose, while GLUT5 only transports fructose (Table 1.2). The consequences 
of uric acid and/or glucose competing with fructose for transport by GLUT9 in the brain 
are currently not known. However, it can be seen by the ISH for these GLUTs that 
GLUT9 is expressed in the hippocampus, while GLUT5 is not expressed at all in this 
region (see Section 4.1.2, Fig 4.3). In addition GLUT9 is expressed in the olfactory bulb 
at higher levels than GLUT5 (Fig 4.5). Both of these regions of the brain were can 
oxidize fructose in reactions where the plasma membrane was left intact (Table 4.4), 
suggesting that in these regions, GLUT9 is responsible for fructose transport.  
Glut6 may also be expressed in some regions of the brain, but it is not known 
whether this GLUT translocates to the plasma membrane or not. Additionally, GLUT6 is 
a 46 kDa protein (Doege et al., 2000). In Western blots of Fru-1-P positive brain regions, 
an antibody against mouse GLUT6 produced a single band at 40 kDa (see Section 4.2.1, 
Fig 4.6). Furthermore, GLUT6 has been shown to be a high Km glucose transporter. 
While GLUT6 possesses a conserved isoleucine seen in some other fructose-transporting 
GLUTs, its kinetic parameters for fructose, or other small molecules, have not been 
described (see Section 1.2.1, Table 1.2). In the work presented here, the role of GLUT6 
in fructose metabolism in the brain, as well as other organs in the body, remains 
speculative.  
 
5.3.2 Predominant fructose-phosphorylating kinases in different tissues 
Once inside cells, fructose will either be phosphorylated by KHK-C (liver, kidneys, small 
intestine), KHK-A (ubiquitous, including brain), or one of the HK isoforms. In brain and 
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skeletal muscle, HK-I and HK-II are the most abundant HK isoforms, respectively (Sols 
& Crane, 1954; Schimke & Grossbard, 1968) (see Section 1.2.2, Table 1.3).  
 In the liver, fructose metabolism proceeds through the Fru-1-P pathway mediated 
by KHK-C. In the brain, it is shown here that both HK-I and KHK-A participate about 
equally in the phosphorylation of fructose, and fructose metabolic flux is through both the 
Fru-6-P and Fru-1-P pathways. Other tissues known to metabolize fructose express 
different ratios of HK isozymes, along with KHK-A or -C. For instance, skeletal muscle 
and adipose tissue express fructose-transporting GLUTs, and are thought to metabolize 
fructose via HK-mediated Fru-6-P pathway exclusively (Renold & Thorn, 1955; Froesch 
& Ginsberg, 1962). However, the relative contribution of kinases in these tissues to 
fructose metabolic flux has not been measured. Additionally, a switch in expression of 
KHK-A to -C seen in cardiac tissue with hypoxia and/or high fructose diets (Mirtschink 
et al., 2015) demonstrates a need to fully characterize KHK activity in different tissues 
and in different diets.  
 Determining whether a substrate will be acted on by a particular enzyme, when 
more than one enzyme is capable of binding the substrate is in the same cell, requires 
comparing the efficacy of the different enzymes towards their substrates and their in vivo 
concentration. This is done by comparing the kcat/Km values of the different enzymes for 
the substrate. Since KHK-C is expressed at the exclusion of KHK-A in the liver, KHK-C 
would compete with HK-IV for the ability to phosphorylate fructose. KHK-C is by far 
more efficient at this (Table 5.2), and it logically follows that hepatic fructose 
metabolism starts with Fru 1-P production.  
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 In the brain, HK-I and KHK-A compete for the ability to phosphorylate fructose. 
While HK-I and KHK-A have Km values toward fructose within 2-fold of each other 
(Table 5.2), HK-I is actually much faster than KHK-A at turning over the 
phosphorylation reaction, giving HK-I a higher efficacy ratio for this reaction. If there 
two proteins were expressed equally in the cell, HK-I should be the major contributor 
toward fructose metabolism. However, in oxidative assays presented here (see 4.2.4, Fig 
4.7), inhibition of either HK or KHK shows that these two kinases each contribute to 
about half of the flux of fructose metabolism. Because HK-I prefers glucose over 10-fold 
to fructose, and glucose is always present in brain (except during periods of hypoxia), 
HK-I may play less of a role in fructose phosphorylation than indicated in Table 5.2.  
 
5.3.3 Predominant aldolase isozymes participating in fructose metabolism by different 
tissues 
Aldolase isozymes differ in tissue distribution and kinetic properties towards cleavage of 
Fru 1-P. Aldolase B is expressed almost exclusively in the liver, and it is the most 
efficient at binding and cleaving Fru 1-P. Thus, aldolase B would be responsible for 
participating in fructose metabolism even if it had to compete with another isozyme. In 
the brain, aldolase A and C are both expressed, in roughly equal concentrations (Rutter et 
al., 1968; Susor et al., 1975). Aldolase C has approximately 10-fold higher efficiency 
toward Fru 1-P cleavage than aldolase A, and is the more likely contributor in fructose 
metabolism in the brain (Table 5.3).  
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Table 5.2 Efficacy of different kinases towards fructose phosphorylation 
 
 
Kinase 
Km values 
toward 
Fru (mM) 
kcat/ Km 
values 
(µM-1s-1) 
Tissue 
Distribution Refs 
HK-IV 158 1.11 Liver Xu et al., 1995  
KHK-C 0.2 35 Liver Bais et al., 1985 
HK-I 3.5 50.3 Brain, ubiquitous 
Raushel & Cleland, 
1973  
KHK-A 7 1.07 Brain, ubiquitous Diggle et al., 2009  
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Table 5.3 Efficacy of different aldolase isozymes towards Fru 1-Pa 
 
Aldolase 
Km values 
toward Fru 
1-P (mM) 
kcat/ Km 
values 
(M-1 s-1) 
Tissue 
Distribution 
A 40.00 0.015 ubiquitious, brain 
B 0.70 2 liver, kidney 
C 16.00 0.175 brain, smooth muscle 
 
aAdapted from Penhoet et al., 1969a and Pezza, 2006. 
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The three aldolase isozymes have low kcat/ Km values, with B > C > A for Fru 1-P 
cleavage, and are relatively slow compared to the production of Fru 1-P by KHK. This 
cleavage is likely to be even slower in the brain than in the liver because of the lack of 
aldolase B. If the creation of a phosphate sink is one of the first metabolic triggers that 
lead to damage from excessive fructose consumption, it is likely happening in brain as 
well as liver, and perhaps to an even more severe degree.  
 
5.4 Developing Treatments for Pathologies of Excessive Fructose Exposure 
Long-term excessive dietary fructose intake is associated with, and increasingly being 
implicated as a cause of, MBS. This is a serious problem as obesity and insulin resistance 
are becoming epidemic often leading to the development of type II diabetes. Thus, 
understanding the enzymes kinetics and expression parameters will allow for better 
prediction of the most influential enzymes to target for therapies. 
 
5.4.1 Current drug interventions that mitigate symptoms of HFI or fructose-induced 
metabolic syndrome 
HFI is caused by an inherited loss of aldolase B activity in the liver, blocking the 
cleavage of Fru 1-P (Hers & Joassin, 1961; Froesch et al., 1963). Currently, the only 
available treatment for patients with HFI is to avoid dietary fructose. Patients are 
diagnosed with MBS when they co-present with three or more of the following 
symptoms: central obesity, elevated serum triglycerides (≥150 mg/dL), hypertension, low 
high-density-lipid cholesterol levels, and increased fasting glucose levels/glucose 
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insensitivity (Reaven, 1997). Since MBS is complex and involves related but distinct 
pathologies, many treatment strategies are pursued that target different aspects of the 
syndrome. These include insulin-sensitizing drugs for patients who have developed 
insulin resistance, and medications to lower blood pressure for patients who have 
developed hypertension. These strategies deal with mitigating the negative effects after 
metabolic remodeling has already occurred, and do not stop the progression of symptoms 
from becoming MBS.  
Increased production of uric acid has been implicated as both a symptom of MBS, 
as well as an agent that furthers metabolic remodeling and dysregulations. Increased 
concentrations of uric acid lead directly to gout, and can contribute to the development of 
other metabolic syndrome symptoms (Nakagawa et al., 2006; Tsouli et al., 2006; Sui et 
al., 2008). The use of allopurinol, a xanthine oxidase inhibitor, or benzbromarone, a 
uricosuric agent, in rat models of fructose metabolism were able to mitigate the 
development of some of the symptoms of MBS, including preventing a raise in 
circulating triglyceride levels and having less insulin resistance after 8 weeks of 60% 
(w/w) fructose diet, compared to control mice without medication (Nakagawa et al., 
2006). The combined use of uric acid reducers and angiotensin-converting enzyme 
inhibitors in rats fed a 60% (w/w) fructose chow for three months also reduced symptoms 
of MBS, including lowering blood pressure and improving insulin resistance (Roncal et 
al., 2009). A study on obese adolescents also found that pharmacologically lowering uric 
acid levels lower blood pressure, and prevented or significantly slowed additional weight 
gain over three months, compared to obese adolescents in the placebo group (Soletsky & 
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Feig, 2012). Are uric acid-lowering medications such as allopurinol a potential treatment 
for humans with MBS, beyond their current use for gout?  
 
5.4.2 Correlation between fructose, insulin resistance, and Alzheimer’s Disease 
Additionally, increased uric acid levels and insulin insensitivity have been correlated with 
the development of inflammation in the brain (de la Monte & Tong, 2014; Zhang et al., 
2014; Willette et al., 2015, defects in learning and memory (Molteni et al., 2002; Messier 
et al., 2007), and the development of Alzheimer’s disease (Farooqui et al., 2012; de la 
Monte & Tong, 2014; Willette et al., 2015) (AD). It has been proposed that AD is a “type 
III diabetes” of the brain (Cholerton et al., 2013; de la Monte & Tong, 2014). While it is 
becoming clear that whole body insulin resistance can disrupt insulin signaling in parts of 
the brain, such as the hypothalamus which is involved in energy-sensing and feeding 
behavior (Zhang et al., 2014), and that insulin resistance in human can predict the 
development of amyloid deposits in middle-aged humans (Willette et al., 2015, the role 
that fructose metabolism by the brain itself has not been investigated. Rats on a high 
fructose diet will develop brain lesions and show impairment in cognitive function, which 
can be improved when rats are treated with the antioxidant quercetin, allopurinol (Zhang 
et al., 2014), or the diabetic treatment drug pioglitazone (Yin et al., 2013). Levels of AD 
are also rising epidemically (Cholerton et al., 2013), much like obesity and MBS, and 
more research on the role of fructose metabolism in the development of this devastating 
neurological condition.  
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5.4.3 Targeting fructose-transporting GLUTs to limit absorption and metabolism of 
dietary fructose 
One possible strategy for preventing dietary fructose metabolism in the treatment of HFI 
or MBS is to block its absorption either from the intestines into the blood stream, or into 
different organs expressing various fructose-transporting GLUTs. While no current 
pharmacological treatments exist for blocking fructose-transport, there is a small 
molecule inhibitor of GLUT5 (1-O-Benzyle-2-N, 3-O-carbonyl-α-L-
sorbofuranosylamine), and there are various KO mouse models that can shed light on the 
usefulness of this as a therapeutic strategy.  
Depletion of GLUT5 transport ability, either by small molecule inhibition or 
siRNAs in cell culture, or KO of the gene in Glut5-/- mice, affects regular adipocyte 
maturation and leads to decreased levels of white adipose tissue (Du & Heaney, 2012) as 
well as fructose malabsorption (Barone et al., 2009). Glut5-/- mice develop hypotension 
and reduced kidney function on a high fructose diet (60% calories in chow), and will die 
from hypovolemic shock after 7-10 days on this diet (Barone et al., 2009). Since reduced 
kidney function is one of the symptoms of MBS trying to be prevented, and nutrient 
malabsorption is not desirable, prevention of fructose-induced obesity or metabolic 
syndrome by small molecule inhibition of GLUT5 to block dietary fructose uptake would 
require patients to also limit fructose consumption. Limiting fructose consumption alone 
would prevent fructose-induced MBS, and would thus negate the need for further drug 
interventions.  
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In human patients lacking GLUT2, or KO mouse models of the other fructose-
transporting 8, and 9, symptoms of MBS appear without introduction of fructose to the 
diet due to the physiological importance of the other molecules transported by these 
proteins other than fructose (see Section 1.2.1). This includes damage and diabetes 
development in GLUT2 deficient patients (Berry et al., 2005), exacerbated symptoms of 
MBS in Glut8-/- mice fed high fructose diets (DeBosch et al., 2012; DeBosch et al., 2013; 
Debosch et al., 2014) and kidney damage and hyperuricosuria in both whole-body and 
liver-specific Glut9-/- mice fed normal diets (Preitner et al., 2009; Preitner et al., 2013). 
Small-molecule inhibitors of these fructose-transporters would likely not impair fructose 
transport without impairing over-all transporting abilities, and thus are not good 
candidates for drug targeting.  
 
5.4.4 Targeting KHK to prevent Fru-1-P flux 
Another potential therapeutic target against Fru-1-P mediated MBS is the 
inhibition of KHK-C activity. A recent study using KHK KO mouse models showed that 
complete loss of both isozymes of KHK (liver-specific, KHK-C, and ubiquitously 
expressed, KHK-A) protected mice from developing MBS following six months of a high 
fructose diet (Ishimoto et al., 2012). This, combined with the evidence that many 
negative consequences of fructose metabolism are due specifically to the Fru-1-P 
mediated pathway, make targeting of KHK an attractive therapeutic candidate.  
However, loss of only KHK-A, the isozyme expressed in the brain, accentuated 
the development of MBS (Ishimoto et al., 2012). Presumably, without metabolism by 
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tissues expressing KHK-A fructose metabolism becomes the sole responsibility of the 
liver, leading to an increase in severity of MBS. The levels of KHK activity from Fru-1-P 
positive brain regions, and the ability of these brain regions to oxidize fructose, 
corroborates this and points to the brain as one of the extra-hepatic sites of fructose 
metabolism. It is important that any small-molecule inhibitor of KHK does not shuttle all 
dietary fructose towards one organ to spare another. Therefore, any small molecules 
would have to be effective towards both KHK isozymes in order to be of use in treating 
HFI or MBS.  
Of the options discussed here, inhibition of KHK offers the most promising 
pharmacological treatment option for treating HFI or fructose-mediated symptoms of 
MBS. The first and best treatment would be prevention of disease by eliminating dietary 
fructose (HFI patients) or restricting fructose consumption to levels found naturally in 
fruit and honey (MBS patients). However, with the use of added sweeteners in 
commercially prepared foods, this type of limitation of dietary fructose is difficult, and 
not fun, making a drug candidate more attractive even if less efficient.  
Currently, generating symptoms of MBS in either WT mice or other mouse 
models requires several months on a high fructose diet (Anstee & Goldin, 2006; 
Takahashi et al., 2006; Wang et al., 2009; Ishimoto et al., 2012), making testing any 
newly developed therapeutics aimed at blocking fructose metabolism lengthy and 
tedious. However, screening these therapies in Aldo2-/- mice offers a clearer and faster 
alternative to current animal models for MBS, since Aldo2-/- mice develop symptoms 
earlier and with lower doses of fructose than other animal models.  
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5.5 Conclusion 
Here, I characterized the Aldo2-/- mouse as a novel model for HFI that closely 
phenocopies the symptoms seen in human patients. Additionally, these mice reveal some 
underappreciated consequences of HFI, such as increased fat build up in liver even when 
fructose does not enter the diet. The Aldo2-/- mouse will also allow for investigation of 
other long-term consequences of HFI seen in human patients that were, until now, 
lacking a model for systematic study of chronic, but non-lethal, fructose doses. Since the 
symptoms of low doses of fructose exposure in HFI patients and high doses of fructose 
ingestion in regular non-HFI patients who develop MBS overlap, the Aldo2-/- mouse may 
also serve to answer questions towards better understanding of the role fructose 
metabolism plays in the development of NAFLD and metabolic syndrome. 
 It is also becoming clear that MBS is a systematic, multi-organ disorder. In this 
light, it is important to identify all organs capable of fructose metabolism. Given the 
results presented here, it is clear that dissected brain regions, consisting of the 
cerebellum, hippocampus, cortex, and olfactory bulb, can oxidize fructose. It has been 
speculated that fructose metabolism outside of the liver proceeds through a Fru-6-P 
pathway mediated by HK, however, no studies to date have been able to quantify 
contributions of HK compared to KHK in any tissue. The results in this thesis results 
show that both HK and KHK contribute to fructose phosphorylation in Fru-1-P positive 
brain tissues. Of special interest is the three-fold increase in KHK activity seen in Fru-1-P 
positive brain regions of mice exposed to a high fructose diet (40% (w/v) fructose 
drinking solution for three weeks). Since KHK is an enzyme specific to fructose 
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metabolism, this indicates that not only is the brain exposed to dietary fructose, but that it 
is also responsive to it.  
The impact that high fructose exposure has on the human brain, which continues 
developing from birth through puberty (Levitt, 2003; Blakemore & Choudhury, 2006), is 
currently unknown. Given that exposure to high concentrations of fructose has toxic 
effects such as hypophosphatemia and hyperuricemia, along with other metabolic 
consequences including lipid dysregulation, and activation of pro-inflammation 
pathways, in liver and kidneys (Mayes, 1993; Rayssiguier et al., 2006, Bergheim, 2008 
#3208; Gersch et al., 2007; Ouyang et al., 2008; Thuy et al., 2008; Nakayama et al., 
2010), it is important to quantify the amount of fructose absorbed by the brain from the 
diet, and the intermediate metabolites of the Fru-1-P pathway.  	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SUMMARY: I am a creative, efficient, and independent researcher with 
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have a passion for investigating the organization of dynamic systems, and how 
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Doctoral Research: Whole-body fructose metabolism: biochemical 
consequences of hereditary fructose intolerance, and extra-hepatic sties of 
fructose metabolism. 
Boston University, Laboratory of Dr. Dean R. Tolan 2008 – Defending Dec, 
2015 
 
• Characterized a novel knockout mouse, the Aldo2-/- mouse, and validated 
this animal as an appropriate model for hereditary fructose intolerance 
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• Histologically characterized livers of Aldo2-/- and wild-type mice for tissue 
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